TY 2013 Form 990

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
(1) Grace Frisone........................................................................ Chair	16.00 .......................	X	X			0	0	0
(2) Michael H Barnett Esq........................................................................ Vice Chair	7.00 .......................	X	X			0	0	0
(3) Nicholas W Raymond........................................................................ Treasurer	12.00 .......................	X	X			0	0	0
(4) Scott Rodgville CPA........................................................................ Secretary	4.00 .......................	X	X			0	0	0
(5) June Kinoshita........................................................................ Director	3.00 .......................	X				0	0	0
(6) Judith Lee........................................................................ Director	5.00 .......................	X				0	0	0
(7) Diane Marcello........................................................................ Director	3.00 .......................	X				0	0	0
(8) Henry Pownall PhD........................................................................ Director	2.00 .......................	X				0	0	0
(9) Brian K Regan PhD........................................................................ Director	4.00 .......................	X				0	0	0
(10) Jonathan Rice Esq........................................................................ Director	3.00 .......................	X				0	0	0
(11) Eltjo R Ed Schoonveld........................................................................ Director	3.00 .......................	X				0	0	0
(12) Stacy Pagos Haller........................................................................ President/CEO	55.00 .......................		X			352,415	0	71,690
(13) Donna Callison........................................................................ VP, Development	45.00 .......................			X		181,739	0	41,308
(14) David F Marks CPA CMA........................................................................ VP, Finance & Administration	45.00 .......................			X		154,253	0	46,283
(15) Guy Eakin Ph D........................................................................ VP, Scientific Affairs	45.00 .......................			X		151,149	0	48,531
(16) Bridget Hart Shea........................................................................ Sr. Dir. Major & Planned Gifts	40.00 .......................				X	123,037	0	23,964

(A) Name and business address	(B) Description of services	(C) Compensation
WildeLW Robbins Associates Inc201 Summer StreetHollistonMA01746	Public awareness consul. & materials	5,382,488
Data Management Inc160 Stone StreetStonevilleNC27048	Database management	216,131
Global Technology Solutions Inc2977 Stewart Loop Unit BFort MeadeMD20755	Building & office services	181,131
Blackbaud Inc2000 Daniel Island DriveCharlestonSC29492	Database management	171,126
EU Services Inc649 Horners LaneRockvilleMD20850	Printing	156,776
2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 6

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1	Grants and other assistance to governments and organizations in the United States. See Part IV, line 21	7,862,765	7,862,765
2	Grants and other assistance to individuals in the United States. See Part IV, line 22	4,000	4,000
3	Grants and other assistance to governments, organizations, and individuals outside the United States. See Part IV, lines 15 and 16	888,550	888,550
4	Benefits paid to or for members
5	Compensation of current officers, directors, trustees, and key employees ....	1,028,650	590,597	255,262	182,791
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) ....
7	Other salaries and wages	2,139,360	1,050,137	698,083	391,140
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	225,963	111,685	73,804	40,474
9	Other employee benefits .......	437,381	216,334	142,648	78,399
10	Payroll taxes ...........	200,472	99,132	65,415	35,925
11	Fees for services (non-employees):
a	Management ......
b	Legal .........	83,044	25,332	57,712
c	Accounting ...........	15,258	10,145	2,487	2,626
d	Lobbying ...........
e	Professional fundraising services. See Part IV, line 17	407,033			407,033
f	Investment management fees ......	151,982		151,982
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O) ........	1,035,589	924,251	84,545	26,793
12	Advertising and promotion ....
13	Office expenses .......	1,363,124	1,034,191	223,051	105,882
14	Information technology ......	547,203	324,781	146,179	76,243
15	Royalties ..
16	Occupancy ...........	334,789	182,397	108,618	43,774
17	Travel ............	232,126	119,655	90,105	22,366
18	Payments of travel or entertainment expenses for any federal, state, or local public officials ......
19	Conferences, conventions, and meetings ....	133,637	125,350	6,639	1,648
20	Interest ...........
21	Payments to affiliates .......
22	Depreciation, depletion, and amortization .....	273,699	147,854	85,894	39,951
23	Insurance ..............	82,850	38,789	29,795	14,266
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	Pub. awareness postage	4,098,157	2,155,178	279,132	1,663,847
b	Pub. awareness printing	1,931,997	707,024	170,392	1,054,581
c	Pub. awareness comp.	932,337	501,479	59,628	371,230
d	List rental	717,414	376,226	46,025	295,163
e	All other expenses
25	Total functional expenses. Add lines 1 through 24e	25,127,380	17,495,852	2,777,396	4,854,132
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).	8,593,054	4,227,648	613,423	3,751,983

Part X Balance Sheet Check if Schedule O contains a response or note to any line in this Part X ..............
	1	Cash–non-interest-bearing .............	3,920,291	1	6,219,243
2	Savings and temporary cash investments .........	1,418,430	2	395,903
3	Pledges and grants receivable, net ...........	5,336,038	3	4,184,603
4	Accounts receivable, net .............		4
5	Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L ..................
			5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete Part II of Schedule L
			6
7	Notes and loans receivable, net .............	176,008	7
8	Inventories for sale or use ..............	19,646	8	16,291
9	Prepaid expenses and deferred charges ..........	104,897	9	46,374
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	11,166,311
b	Less: accumulated depreciation .....	10b	2,781,227	8,602,822	10c	8,385,084
11	Investments—publicly traded securities ..........	19,464,859	11	24,677,383
12	Investments—other securities. See Part IV, line 11 .....	2,364,446	12	3,425,000
13	Investments—program-related. See Part IV, line 11 .....		13
14	Intangible assets ...............		14
15	Other assets. See Part IV, line 11 ...........	831,452	15	831,794
16	Total assets. Add lines 1 through 15 (must equal line 34)......	42,238,889	16	48,181,675
	17	Accounts payable and accrued expenses .........	584,225	17	689,531
18	Grants payable .................	11,924,959	18	14,604,652
19	Deferred revenue ................		19
20	Tax-exempt bond liabilities .............		20
21	Escrow or custodial account liability. Complete Part IV of Schedule D..		21
22	Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........		22
23	Secured mortgages and notes payable to unrelated third parties ..		23
24	Unsecured notes and loans payable to unrelated third parties ....		24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D....................	1,695,477	25	1,534,970
26	Total liabilities. Add lines 17 through 25.........	14,204,661	26	16,829,153
		Organizations that follow SFAS 117 (ASC 958), check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets ..............	15,916,258	27	18,308,429
28	Temporarily restricted net assets ...........	12,027,970	28	12,954,093
29	Permanently restricted net assets ...........	90,000	29	90,000
	Organizations that do not follow SFAS 117 (ASC 958), check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds ........		30
31	Paid-in or capital surplus, or land, building or equipment fund .....		31
32	Retained earnings, endowment, accumulated income, or other funds		32
33	Total net assets or fund balances ...........	28,034,228	33	31,352,522
34	Total liabilities and net assets/fund balances ........	42,238,889	34	48,181,675

- TIN:

SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.
right arrow

Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public
Inspection

Name of the organization

BrightFocus Foundation

Employer identification number

23-7337229

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 11, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E.)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in

section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An organization that normally receives: (1) more than 331/3% of its support from contributions, membership fees, and gross

receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of

its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses

acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box that describes the type of supporting organization and complete lines 11e through 11h.

Type I

Type II

Type III - Functionally integrated

Type III - Non-functionally integrated

By checking this box, I certify that the organization is not controlled directly or indirectly by one or more disqualified persons other than foundation managers and other than one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2).

If the organization received a written determination from the IRS that it is a Type I, Type II, or Type III supporting organization, check this box ..................................................

Since August 17, 2006, has the organization accepted any gift or contribution from any of the
following persons?

(i) A person who directly or indirectly controls, either alone or together with persons described in (ii)

Yes

and (iii) below, the governing body of the supported organization? ................

11g(i)

(ii) A family member of a person described in (i) above? ......................

11g(ii)

(iii) A 35% controlled entity of a person described in (i) or (ii) above? ................

11g(iii)

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization in col. (i) listed in your governing document?		(v) Did you notify the organization in col. (i) of your support?		(vi) Is the organization in col. (i) organized in the U.S.?		(vii) Amount of monetary support
(i) Name of supported organization	(ii) EIN	Yes	No	Yes	No	Yes	No	(vii) Amount of monetary support


Total

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990EZ.

Cat. No. 11285F

Schedule A (Form 990 or 990-EZ) 2013

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2009	(b) 2010	(c) 2011	(d) 2012	(e) 2013	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") ....	21,879,337	18,261,062	22,601,859	23,534,029	25,126,233	111,402,520
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.......
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3	21,879,337	18,261,062	22,601,859	23,534,029	25,126,233	111,402,520
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f)..
6	Public support. Subtract line 5 from line 4.						111,402,520

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2009	(b) 2010	(c) 2011	(d) 2012	(e) 2013	(f) Total
7	Amounts from line 4..	21,879,337	18,261,062	22,601,859	23,534,029	25,126,233	111,402,520
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...	1,572,008	1,443,239	1,345,423	1,323,906	1,539,583	7,224,159
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.)..	1,132	14	16			1,162
11	Total support (Add lines 7 through 10).						118,627,841

Gross receipts from related activities, etc. (see instructions) ..................

37,705

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization, check this box and stop here................................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2013 (line 6, column (f) divided by line 11, column (f)) .........

93.910 %

Public support percentage for 2012 Schedule A, Part II, line 14 ...............

93.650 %

16a

33 1/3% support test—2013. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2012. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2013. If the organization did not check a box on line 13, 16a, or 16b, and line 14
is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain
in Part IV how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported
organization ..................................................... right arrow

10%-facts-and-circumstances test—2012. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line
15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here.
Explain in Part IV how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly
supported organization ................................................ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990 or 990-EZ) 2013

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 9 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2009	(b) 2010	(c) 2011	(d) 2012	(e) 2013	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose......
3	Gross receipts from activities that are not an unrelated trade or business under section 513..
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge..
6	Total. Add lines 1 through 5.
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons...
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2009	(b) 2010	(c) 2011	(d) 2012	(e) 2013	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization,
check this box and stop here............................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2013 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2012 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2013 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2012 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests—2013. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ........ right arrow

33 1/3% support tests—2012. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ..... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions ..... right arrow

Schedule A (Form 990 or 990-EZ) 2013

Page 4

Part IV

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; and Part III, line 12. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Explanation

Schedule A (Form 990 or 990-EZ) 2013

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990, 990-EZ,
or 990-PF)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

Information about Schedule B (Form 990, 990-EZ, or 990-PF) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Name of the organization

BrightFocus Foundation

Employer identification number

23-7337229

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note. Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, $5,000 or more (in money or
property) from any one contributor. Complete Parts I and II.

Special Rules

For a section 501(c)(3) organization filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi) and received from any one contributor, during the year, a contribution of the
greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For a section 501(c)(7), (8), or (10) organization filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 for use exclusively for religious, charitable,
scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I, II, and
III.

For a section 501(c)(7), (8), or (10) organization filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions for use exclusively for religious, charitable, etc., purposes, but these contributions did
not total more than $1,000. If this box is checked, enter here the total contributions that were received during
the year for an exclusively religious, charitable, etc., purpose. Do not complete any of the parts unless the General Rule
applies to this organization because it received nonexclusively religious, charitable, etc., contributions of $5,000 or more
during the year ......................... Arrow Bullet

Caution. An organization that is not covered by the General Rule and/or the Special Rules does not file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its
Form 990-EZ or on its Form 990PF, Part I, line 2, to certify that it does not meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990, 990-EZ, or 990-PF) (2013)

Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Page 2

Name of organization BrightFocus Foundation

Part I	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	RESTRICTED RESTRICTED RESTRICTED RESTRICTED, RESTRICTEDRESTRICTED	$RESTRICTED	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Page 3

Name of organization BrightFocus Foundation

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (see instructions)	(d) Date received
		$
Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Page 4

Name of organization
BrightFocus Foundation

Employer identification number

23-7337229

Part III

Exclusively religious, charitable, etc., individual contributions to section 501(c)(7), (8), or (10) organizations
that total more than $1,000 for the year. Complete columns (a) through (e) and the following line entry.
For organizations completing Part III, enter the total of exclusively religious, charitable, etc.,
contributions of $1,000 or less for the year. (Enter this information once. See instructions.) Arrow Bullet

$
Use duplicate copies of Part III if additional space is needed.

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No.
from
Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990, 990-EZ, or 990-PF) (2013)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE C
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527
SchCMd Bullet

Complete if the organization is described below. SchCMd Bullet

Attach to Form 990 or Form 990-EZ.
SchCMd Bullet

See separate instructions. SchCMd Bullet

Information about Schedule C (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public
Inspection

If the organization answered "Yes" to Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then
Round Bullet

Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
Round Bullet

Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
Round Bullet

Section 527 organizations: Complete Part I-A only.
If the organization answered "Yes" to Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then
Round Bullet

Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
Round Bullet

Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.
If the organization answered "Yes" to Form 990, Part IV, Line 5 (Proxy Tax) or Form 990-EZ, Part V, line 35c (Proxy Tax), then
Round Bullet

Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of the organization

BrightFocus Foundation

Employer identification number

23-7337229

Part I-A

Complete if the organization is exempt under section 501(c) or is a section 527 organization.

Provide a description of the organization’s direct and indirect political campaign activities in Part IV.

Political expenditures .................................... SchCMd Bullet

Volunteer hours ........................................

Part I-B

Complete if the organization is exempt under section 501(c)(3).

Enter the amount of any excise tax incurred by the organization under section 4955 ......... SchCMd Bullet

Enter the amount of any excise tax incurred by organization managers under section 4955 ...... SchCMd Bullet

If the organization incurred a section 4955 tax, did it file Form 4720 for this year? ..............

Yes No

Was a correction made? .........................................

Yes No

If "Yes," describe in Part IV.

Part I-C

Complete if the organization is exempt under section 501(c), except section 501(c)(3).

Enter the amount directly expended by the filing organization for section 527 exempt function activities SchCMd Bullet

Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ................................... SchCMd Bullet

Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b.. SchCMd Bullet

Did the filing organization file Form 1120-POL for this year? ..........................

Yes No

Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing
organization made payments. For each organization listed, enter the amount paid from the filing organization’s funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.

For Paperwork Reduction Act Notice, see the instructions for Form 990 or 990-EZ.

Cat. No. 50084S

Schedule C (Form 990 or 990-EZ) 2013

Page 2

Part II-A

Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

A Check SchCMd Bullet

if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
B Check SchCMd Bullet

if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(a) Filing organization's totals	(b) Affiliated group totals
1a	Total lobbying expenditures to influence public opinion (grass roots lobbying) ......
b	Total lobbying expenditures to influence a legislative body (direct lobbying) .......
c	Total lobbying expenditures (add lines 1a and 1b) ...................
d	Other exempt purpose expenditures ........................	24,720,347
e	Total exempt purpose expenditures (add lines 1c and 1d) ...............	24,720,347
f	Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000
	If the amount on line 1e, column (a) or (b) is:The lobbying nontaxable amount is:
	Not over $500,00020% of the amount on line 1e.
	Over $500,000 but not over $1,000,000$100,000 plus 15% of the excess over $500,000.
	Over $1,000,000 but not over $1,500,000$175,000 plus 10% of the excess over $1,000,000.
	Over $1,500,000 but not over $17,000,000$225,000 plus 5% of the excess over $1,500,000.
	Over $17,000,000$1,000,000.

g	Grassroots nontaxable amount (enter 25% of line 1f) .................	250,000
h	Subtract line 1g from line 1a. If zero or less, enter -0-. ................	0
i	Subtract line 1f from line 1c. If zero or less, enter -0-. ................	0
j	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ......................................		Yes No

4-Year Averaging Period Under Section 501(h) (Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the instructions for lines 2a through 2f on page 4.)
Lobbying Expenditures During 4-Year Averaging Period
	Calendar year (or fiscal year beginning in)	(a) 2010	(b) 2011	(c) 2012	(d) 2013	(e) Total

2a	Lobbying nontaxable amount	1,000,000	1,000,000	1,000,000	1,000,000	4,000,000

b	Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000

c	Total lobbying expenditures

d	Grassroots nontaxable amount	250,000	250,000	250,000	250,000	1,000,000

e	Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000

f	Grassroots lobbying expenditures

Schedule C (Form 990 or 990-EZ) 2013

Page 3

Part II-B

Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response to lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.

(a)

Yes

(b)

Amount

During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:

Volunteers? .........................................

Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? ....

Media advertisements? ....................................

Mailings to members, legislators, or the public? .........................

Publications, or published or broadcast statements? .......................

Grants to other organizations for lobbying purposes? .......................

Direct contact with legislators, their staffs, government officials, or a legislative body? ........

Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means? ......

Other activities? ..........................

Total. Add lines 1c through 1i ...............................

Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? .....

If "Yes," enter the amount of any tax incurred under section 4912 .................

If "Yes," enter the amount of any tax incurred by organization managers under section 4912 .....

If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year? .......

Part III-A

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Yes

Were substantially all (90% or more) dues received nondeductible by members? ................

Did the organization make only in-house lobbying expenditures of $2,000 or less? ................

Did the organization agree to carry over lobbying and political expenditures from the prior year? ..........

Part III-B

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered “Yes."

Dues, assessments and similar amounts from members .....................

Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political
expenses for which the section 527(f) tax was paid).

Current year .........................................

Carryover from last year ....................................

Total ............................................

Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .

If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year? ................................

Taxable amount of lobbying and political expenditures (see instructions) ..............

Part IV

Supplemental Information

Provide the descriptions required for Part l-A, line 1; Part l-B, line 4; Part l-C, line 5; Part II-A (affiliated group list); Part II-A, line 2; and Part ll-B, line 1. Also, complete this part for any additional information.

Return Reference	Explanation

Schedule C (Form 990 or 990EZ) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," to Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b
SchDMd Bullet

Attach to Form 990. SchDMd Bullet

See separate instructions. SchDMd Bullet

Information about Schedule D (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization

BrightFocus Foundation

Employer identification number

23-7337229

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" to Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate contributions to (during year) ...
3	Aggregate grants from (during year) .....
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised
funds are the organization's property, subject to the organization's exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be
used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements. Complete if the organization answered "Yes" to Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements .......................	2a
b	Total acreage restricted by conservation easements ..................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 8/17/06, and not on a historic structure listed in the National Register ....................	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during
the tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and
enforcement of the conservation easements it holds? .............................

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .......................................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" to Form 990, Part IV, line 8.

If the organization elected, as permitted under SFAS 116 (ASC 958), not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under SFAS 116 (ASC 958), to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenues included in Form 990, Part VIII, line 1 ........................ SchDMd Bullet

(ii)

Assets included in Form 990, Part X .............................. SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under SFAS 116 (ASC 958) relating to these items:

Revenues included in Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2013

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?........

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" to Form 990,
Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No

If "Yes," explain the arrangement in Part XIII and complete the following table:


c	Beginning balance .................................	1c
d	Additions during the year ..............................	1d
e	Distributions during the year .............................	1e
f	Ending balance ...................................	1f

Did the organization include an amount on Form 990, Part X, line 21? .....................

Yes No

If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ........

Part V

Endowment Funds. Complete if the organization answered "Yes" to Form 990, Part IV, line 10.

		(a)Current year	(b)Prior year	b (c)Two years back	(d)Three years back	(e)Four years back
1a	Beginning of year balance ....	90,000	90,000	90,000	90,000	90,000
b	Contributions ........	3,933	2,316	1,312	3,792	3,715
c	Net investment earnings, gains, and losses
d	Grants or scholarships .....
e	Other expenditures for facilities and programs ........	3,933	2,316	1,312	3,792	3,715
f	Administrative expenses ....
g	End of year balance ......	90,000	90,000	90,000	90,000	90,000

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

0 %

Permanent endowment SchDMd Bullet

100.000 %

Temporarily restricted endowment SchDMd Bullet

0 %

The percentages in lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) unrelated organizations ........................

3a(i)

Yes

(ii) related organizations ........................

3a(ii)

If "Yes" to 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property		(a) Cost or other basis (investment)	(b)Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a	Land .................	2,800,000	1,147,363		3,947,363
b	Buildings ................	1,629,400	4,651,844	2,046,923	4,234,321
c	Leasehold improvements ............
d	Equipment ................		750,379	560,597	189,782
e	Other .................		187,325	173,707	13,618
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).).......					8,385,084

Schedule D (Form 990) 2013

Page 3

Part VII

InvestmentsOther Securities. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b)Book value	(c) Method of valuation: Cost or end-of-year market value
(1)Financial derivatives
(2)Closely-held equity interests
(3)Other (A) Alternative investments - hedge fund	3,425,000	F








Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)	3,425,000

Part VIII

InvestmentsProgram Related. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment		(b) Book value	(c) Method of valuation: Cost or end-of-year market value









Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description				(b) Book value









Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........

Part X

Other Liabilities. Complete if the organization answered 'Yes' to Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1.(a) Description of liability		(b) Book value
Federal income taxes
Charitable gift annuities		1,346,011
Rental deposits		80,000
Capital lease obligations		108,959






Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)		1,534,970
2. Liability for uncertain tax positions In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII ..................................................

Schedule D (Form 990) 2013

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return Complete if the organization answered 'Yes' to Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......			1	45,927,920
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains on investments ..........	2a	1,580,201
b	Donated services and use of facilities .........	2b	17,597,705
c	Recoveries of prior year grants ...........	2c	136,575
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d .....................			2e	19,314,481
3	Subtract line 2e from line 1.....................			3	26,613,439
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a	151,982
b	Other (Describe in Part XIII.) ...........	4b	-41,779
c	Add lines 4a and 4b.......................			4c	110,203
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......			5	26,723,642

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' to Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........			1	42,609,626
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities ..........	2a	17,597,705
b	Prior year adjustments ..............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d......................			2e	17,597,705
3	Subtract line 2e from line 1.....................			3	25,011,921
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a	151,982
b	Other (Describe in Part XIII.) ............	4b	-36,523
c	Add lines 4a and 4b.......................			4c	115,459
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......			5	25,127,380

Part XIII

Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b;
Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference	Explanation
Part V, Line 4:	The earnings on this endowment are available for the Alzheimer's Disease Research program and are recorded as temporarily restricted investment income, and are released as spent.
Part X, Line 2:	BrightFocus performed an evaluation of uncertain tax positions for the year ended March 31, 2014, and determined that there were no matters that would require recognition in the consolidated financial statements or that may have any effect on its tax-exempt status.
Part XI, Line 4b - Other Adjustments:	Depreciation on rental property -41,779.
Part XII, Line 4b - Other Adjustments:	Depreciation on rental property -41,779. Change in present value of grants 5,256.

Schedule D (Form 990) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE F(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990,Part IV, line 14b, 15, or 16. Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

See separate instructions. Right pointing arrow large image

Information about Schedule F (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization
BrightFocus Foundation

Employer identification number

23-7337229

Part I

General Information on Activities Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 14b.

For grantmakers.Does the organization maintain records to substantiate the amount of its grants and

other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used

to award the grants or assistance? ...............................

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.

Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region		(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in region	(d) Activities conducted in region (by type) (e.g., fundraising, program services, investments, grants to recipients located in the region)	(f) Total expenditures for and investments in region
	East Asia and the Pacific - Australia, Brunei, Burma, Cambodia,	0	0	Grantmaking	99,550
	Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium	0	0	Grantmaking	539,000
	Middle East and North Africa - Algeria, Bahrain, Djibouti, Egypt,	0	0	Grantmaking	250,000














3a	Sub-total .....	0	0		888,550
b	Total from continuation sheets to Part I ...	0	0		0
c	Totals (add lines 3a and 3b)	0	0		888,550

For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2013

Schedule F (Form 990) 2013

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement
East Asia and the Pacific	National Glaucoma Research by David Mackey, MD Entitled: (G2014032)	99,550	Wire
Middle East and North Africa	Alzheimer's Disease Research by Michal Schnaider Beeri, PhD Entitled: (A2014268S)	250,000	Wire
Europe (Including Iceland & Greenland)	Alzheimer's Disease Research by Elena Marcello, PhD Entitled: (A2014314F)	120,000	Wire
Europe (Including Iceland & Greenland)	Alzheimer's Disease Research by Enrico Glaab, PhD Entitled:	50,000	Wire
Europe (Including Iceland & Greenland)	Alzheimer's Disease Research by Rik Ossenkoppele, PhD Entitled: (A2014083F)	120,000	Wire
Europe (Including Iceland & Greenland)	Alzheimer's Disease Research by Carlos Saura, PhD Entitled: (A2014417S)	249,000	Wire

Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .... MediumBullet

Enter total number of other organizations or entities ....................... MediumBullet

Schedule F (Form 990) 2013

Schedule F (Form 990) 2013Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of non-cash assistance	(g) Description of non-cash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2013

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2013

Page 5

Part V

Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information (see instructions).

ReturnReference	Explanation
Part I, Line 2:	BrightFocus interacts with all grantees at least quarterly by e-mail or at scientific meetings. In addition to these interactions, each grant recipient is required to submit separate detailed annual Scientific Progress and Financial Reports to BrightFocus. These are received by the BrightFocus Scientific Affairs department, and reviewed by scientific staff with broad expertise in molecular biology, cell biology, biochemistry, imaging and genetics. Senior staff reviews each Progress Report and evaluates the project for sufficient progress towards the specific aims proposed in the original application or any budgetary concerns. This effort is supported by additional scientific counsel from members of the BrightFocus Scientific Review Committees, when required. In addition to statements of experimental progress, all grantees are asked to report any technical publications, media reports, or patent applications in which BrightFocus-sponsored research is described. If significant concerns related to progress on the awards are discovered, and not resolved after interaction with the award grantee, the BrightFocus staff recommends appropriate actions to the Chair of the Board of Directors Grants Committee. The Scientific Affairs senior staff is empowered to authorize the withholding of funding, or discontinuation of awards, for any grantees that fail to achieve sufficient progress or fail to submit required reports. At the conclusion of the grant award period, each grantee must complete and submit a Final Report that is also reviewed by the BrightFocus senior scientific staff. Evaluation of the work of each grantee is qualitatively and quantitatively assessed through various metrics related to the impact of the grant on its targeted disease field. Such impact metrics have revealed that 95% of BrightFocus-supported research results in research publications that advance the fields served by BrightFocus. This impact is further supported by annual citation analysis that compares BrightFocus-supported works to a statistical sample of works supported by either the US Federal Government or that of other funding agencies. BrightFocus-supported publications are consistently cited at nearly twice the frequency of any other comparison group. A final example of impact assessment revealed that the successes of BrightFocus grantees continue long after the grant expires. On average, each grantee receives 2.2 additional grants for projects spawned by the BrightFocus grant. These come at values nearly 10 times the level of the initial BrightFocus investment. BrightFocus solicits feedback from its grantees, and provides an anonymous forum for collecting such information. Through the BrightFocus Foundation website and within In the Final Scientific Progress Report, there are designated sections where awardees are asked to provide feedback to the foundation. Through this mechanism, they are given the ability to anonymously provide feedback or communicate their concerns to Program Staff or the BrightFocus' Compliance Office. Any suggestions, concerns, complaints, or positive experiences can be outlined and brought to the attention of BrightFocus in this manner, so that BrightFocus can address any areas needing improvement, reaffirm praise-worthy policies, or otherwise assess needs for programmatic change. The senior Scientific Staff present and summarize the status and progress on grants to the BrightFocus Board of Directors at each of their quarterly Board Meetings.

Schedule F (Form 990) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE G (Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information Regarding
Fundraising or Gaming Activities

Complete if the organization answered "Yes" to Form 990, Part IV, lines 17, 18, or 19, or if the organization entered more than $15,000 on Form 990-EZ, line 6a. right arrow

Attach to Form 990 or Form 990-EZ. right arrow

See separate instructions.
right arrow

Information about Schedule G (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization
BrightFocus Foundation

Employer identification number

23-7337229

Part I

Fundraising Activities. Complete if the organization answered "Yes" to Form 990, Part IV, line 17.

Form 990-EZ filers are not required to complete this part.

Indicate whether the organization raised funds through any of the following activities. Check all that apply.

a	Mail solicitations	e	Solicitation of non-government grants
b	Internet and email solicitations	f	Solicitation of government grants
c	Phone solicitations	g	Special fundraising events
d	In-person solicitations

Did the organization have a written or oral agreement with any individual (including officers, directors, trustees

or key employees listed in Form 990, Part VII) or entity in connection with professional fundraising services?

Yes

If "Yes," list the ten highest paid individuals or entities (fundraisers) pursuant to agreements under which the fundraiser is
to be compensated at least $5,000 by the organization.

(i) Name and address of individual or entity (fundraiser)		(ii) Activity	(iii) Did fundraiser have custody or control of contributions?		(iv) Gross receipts from activity	(v) Amount paid to (or retained by) fundraiser listed in col. (i)	(vi) Amount paid to (or retained by) organization
			Yes	No
	WildeLW Robbins Associates Inc 201 Summer Street Holliston, MA07146	Fundraising and communications consultant		No	16,091,182	407,033	15,684,149









Total .................					16,091,182	407,033	15,684,149

List all states in which the organization is registered or licensed to solicit contributions or has been notified it is exempt from registration or licensing.

AL, AK, AZ, AR, CA, CO, CT, DC, FL, GA, HI, IL, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, UT, VA, WA, WV, WI

For Paperwork Reduction Act Notice, see the Instructions for Form 990or 990-EZ.

Cat. No. 50083H

Schedule G (Form 990 or 990-EZ) 2013

Page 2

Part II

Fundraising Events. Complete if the organization answered "Yes" to Form 990, Part IV, line 18, or reported more than $15,000 of fundraising event contributions and gross income on Form 990-EZ, lines 1 and 6b. List events with gross receipts greater than $5,000.

			(a) Event #1 (event type)	(b) Event #2 (event type)	(c) Other events (total number)	(d) Total events (add col. (a) through col. (c))
	1	Gross receipts . . .
	2	Less: Contributions . .
	3	Gross income (line 1 minus line 2) . . .
	4	Cash prizes . . .
	5	Noncash prizes . .
	6	Rent/facility costs . .
	7	Food and beverages .
	8	Entertainment . . .
	9	Other direct expenses .
	10	Direct expense summary. Add lines 4 through 9 in column (d) ...........
	11	Net income summary. Subtract line 10 from line 3, column (d)...........

Part III

Gaming. Complete if the organization answered "Yes" to Form 990, Part IV, line 19, or reported more than $15,000 on Form 990-EZ, line 6a.

(a) Bingo

(b) Pull tabs/Instant
bingo/progressive bingo

(c) Other gaming

(d) Total gaming (add col.(a) through col.(c))

Gross revenue . . . .

Cash prizes . . . .

Non-cash prizes . . .

Rent/facility costs . . .

Other direct expenses . .

Volunteer labor . . .

	Yes %
	No

	Yes %
	No

	Yes %
	No

Direct expense summary. Add lines 2 through 5 in column (d) ........... right arrow

Net gaming income summary. Subtract line 7 from line 1, column (d) ......... right arrow

Enter the state(s) in which the organization operates gaming activities:

Is the organization licensed to operate gaming activities in each of these states? ............

YesNo

If "No," explain:

10a

Were any of the organization's gaming licenses revoked, suspended or terminated during the tax year? .....

YesNo

If "Yes," explain:

Schedule G (Form 990 or 990-EZ) 2013

Page 3

Does the organization operate gaming activities with nonmembers? .................

YesNo

Is the organization a grantor, beneficiary or trustee of a trust or a member of a partnership or other entity

formed to administer charitable gaming? ..........................

YesNo

Indicate the percentage of gaming activity operated in:

The organization's facility ......................

13a

An outside facility ........................

13b

Enter the name and address of the person who prepares the organization's gaming/special events books and records:

Name

Address

15a

Does the organization have a contract with a third party from whom the organization receives gaming

revenue? ......................................

YesNo

If "Yes," enter the amount of gaming revenue received by the organization right arrow

$ and the

amount of gaming revenue retained by the third party right arrow

$ .

If "Yes," enter name and address of the third party:

Name

Address

Gaming manager information:

Name

Gaming manager compensation right arrow

Description of services provided right arrow

Director/officer Employee Independent contractor

Mandatory distributions:

Is the organization required under state law to make charitable distributions from the gaming proceeds to

retain the state gaming license? ............................

YesNo

Enter the amount of distributions required under state law distributed to other exempt organizations or spent

in the organization's own exempt activities during the tax year right arrow

Part IV

Supplemental Information. Provide the explanations required by Part I, line 2b, columns (iii) and (v), and Part III, lines 9, 9b, 10b, 15b, 15c, 16, and 17b, as applicable. Also complete this part to provide any additional information (see instructions).

Return Reference

Explanation

Schedule G, Part I, Line 2b, Column (v)

In the contract with Wilde/LW Robbins Associates, Inc., the management fees are fixed amounts per month for in-scope services that totals $951,319 per year of which $544,286 has been allocated under Part XI, line 11(g) to program and management and are not considered to be the professional fundraising consultant fee. Work performed out of the scope of fundraising counsel services are approved by BrightFocus before they are performed and paid. During the year ended, $4,100,338 was paid to Wilde/WL Robbins Associates, Inc. for production and mailing of public awareness materials, and is included in Part XI, 13, 24 (b), (c) & (d).

Schedule G (Form 990 or 990-EZ) 2013

Additional Data

Software ID:
Software Version:

- TIN:

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," to Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990
lBullet

Information about Schedule I (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public
Inspection

Name of the organization
BrightFocus Foundation

Employer identification number
23-7337229

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ....................................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Governments and Organizations in the United States. Complete if the organization answered "Yes" to
Form 990, Part IV, line 21, for any recipient that received more than $5,000. Part II can be duplicated if additional space is needed.

(a) Name and address of organization or government	(b) EIN	(c) IRC Code section if applicable	(d) Amount of cash grant	(h) Purpose of grant or assistance
(1) Boston University 72 East Concord Street Boston,MA02118	04-2103547	501(c)(3)	16,000	Alzheimer's Disease Research by Benjamin Wolozin, MD, PhD Entitled: (A2012054)
(2) University of Pennsylvania School of Medicine 3451 Walnut Street Philadelphia,PA19104	23-1352685	501(c)(3)	120,000	Alzheimer's Disease Research by Jing Guo, PhD Entitled: (A2014005F)
(3) University of Rochester Medical Center 601 Elmwood Ave Rochester,NY14642	16-0743209	501(c)(3)	250,000	Alzheimer's Disease Research by Gail Johnson, PhD Entitled: (A2014018S)
(4) University of Kentucky 109 Kinkead Hall Lexington,KY40506	61-6033693	501(c)(3)	244,926	Alzheimer's Disease Research by Harry LeVine, III, PhD Entitled: (A2014044S)
(5) University of Florida 1600 SW Archer Road Gainesville,FL32611	59-6002052	501(c)(3)	248,009	Alzheimer's Disease Research by Yona Levites, PhD Entitled: (A2014105S)
(6) University of Florida 1600 SW Archer Road Gainesville,FL32611	59-6002052	501(c)(3)	249,703	Alzheimer's Disease Research by Guilian Xu, PhD Entitled: (A2014108S)
(7) Mayo Clinic Jacksonville 4500 San Pablo Road South Jacksonville,FL32224	59-3337028	501(c)(3)	120,000	Alzheimer's Disease Research by Mitsuru Shinohara, PhD Entitled: (A2014137F)
(8) Washington University 660 South Euclid Ave St Louis,MO63110	91-6001537	501(c)(3)	120,000	Alzheimer's Disease Research by Kristen Funk, PhD Entitled: (A2014164F)
(9) Columbia University Medical Center 630 West 168th Street New York,NY10032	13-5598093	501(c)(3)	120,000	Alzheimer's Disease Research by Tal Nuriel, PhD Entitled: (A2014200F)
(10) University of Kentucky 109 Kinkead Hall Lexington,KY40506	61-6033693	501(c)(3)	250,000	Alzheimer's Disease Research by Steven Estus, PhD Entitled: (A2014210S)
(11) University of Washington School of Medicine 4333 Brooklyn Ave NE Seattle,WA98195	91-6001534	501(c)(3)	250,000	Alzheimer's Disease Research by Richard Morrison, PhD Entitled: (A2014237S)
(12) Washington University 660 South Euclid Ave St Louis,MO63110	91-6001537	501(c)(3)	250,000	Alzheimer's Disease Research by David Brody, MD, PhD Entitled: (A2014270S)
(13) University of Kentucky 109 Kinkead Hall Lexington,KY40506	61-6033693	501(c)(3)	250,000	Alzheimer's Disease Reasearch by M. Paul Murphy, MA, PhD Entitled: (A2014280S)
(14) Washington University 660 South Euclid Ave St Louis,MO63110	91-6001537	501(c)(3)	250,000	Alzheimer's Disease Research by Richard Perrin, MD, PhD Entitled: (A2014296S)
(15) The Ohio State University 1960 Kenny Road Columbus,OH43210	31-6401599	501(c)(3)	250,000	Alzheimer's Disease Research by Chien-liang Lin, PhD Entitled: (A2014315S)
(16) University of Chicago 5801 South Ellis Ave Chicago,IL60637	36-2177139	501(c)(3)	120,000	Alzheimer's Disease Research by Virginie Buggia-Prevot, PhD Entitled: (A2014316F)
(17) Northwestern University 633 Clark Street Evanston,IL60208	36-2167817	501(c)(3)	120,000	Alzheimer's Disease Research by Jian Li, PhD Entitled: (A2014349F)
(18) Washington University 660 South Euclid Ave St Louis,MO63110	91-6001537	501(c)(3)	250,000	Alzheimer's Disease Research by Randall Bateman, MD Entitled: (A2014384S)
(19) University of South Dakota 414 E Clark Street Vermillion,SD57069	46-6003541	501(c)(3)	250,000	Alzheimer's Disease Research by Hongmin Wang, PhD Entitled: (A2014420S)
(20) Stanford University 300 Pasteur Drive Stanford,CA94305	94-1156365	501(c)(3)	250,000	Alzheimer's Disease Research by Katrin Andreasson, MD Entitled: (A2014423S)
(21) Columbia University Medical Center 630 West 168th Street New York,NY10032	13-5598093	501(c)(3)	120,000	Alzheimer's Disease Research by Alice Lepelley, PhD Entitled: (A2014425F)
(22) Seattle Institute for Biomedical and Clinical Research 1660 S Columbian Way 151 F Seattle,WA98108	91-1452438	501(c)(3)	250,000	Alzheimer's Disease Research by Brian Kraemer, PhD Entitled: (A2014438S)
(23) Alzheimer's Drug Discovery Foundation 57 West 57th Street Suite 904 New York,NY10019	20-1082179	501(c)(3)	20,000	Access Platform seeks to pair academic researchers with contract research organizations
(24) Sage Bionetworks 1100 Fairview Ave N Seattle,WA98109	26-4489946	501(c)(3)	50,000	Support for DREAM 8.5 Alzheimer's Disease Big Data Challenge #1.
(25) University of California San Diego 9500 Gilman Drive La Jolla,CA92093	95-6006144	501(c)(3)	200,000	National Glaucoma Research by Jeffrey L Goldberg, MD, PhD Entitled: (C2015200)
(26) University of California San Francisco 3333 California Street Suite 315 San Francisco,CA94143	94-6036493	501(c)(3)	100,000	National Glaucoma Research by Douglas Gould, PhD Entitled: (G2014007)
(27) Washington University 660 South Euclid Ave St Louis,MO63110	91-6001537	501(c)(3)	100,000	National Glaucoma Research by Jeff Gidday, PhD Entitled: (G2014012)
(28) University of Wisconsin 21 N Park Street Suite 6401 Madison,WI53715	39-6006492	501(c)(3)	100,000	National Glaucoma Research by Donna Peters, PhD Entitled: (G2014051)
(29) Oregon Health and Science University 3181 SW Terwilliger Blvd Portland,OR97239	93-1176109	501(c)(3)	100,000	National Glaucoma Research by Janice Vranka, PhD Entitled: (G2014058)
(30) Legacy Health System 1225 NE 2nd Ave Portland,OR97232	93-0386823	501(c)(3)	100,000	National Glaucoma Research by Lin Wang, MD, PhD Entitled: (G2014059)
(31) University of North Texas Health Science Center 3500 Camp Bowie Blvd Fort Worth,TX76107	75-6064033	501(c)(3)	100,000	National Glaucoma Research by Colleen McDowell, PhD Entitled: (G2014063)
(32) University of Nebraska Medical Center 987835 Nebraska Medical Center Omaha,NE68198	47-0049123	501(c)(3)	98,727	National Glaucoma Research by Dhirendra Singh, PhD Entitled: (G2014067)
(33) Duke University Eye Center 106 Science Center Drive Durham,NC27705	56-0532129	501(c)(3)	100,000	National Glaucoma Research by Stuart McKinnon, MD, PhD Entitled: (G2014076)
(34) University of Pittsburgh 4200 Fifth Avenue Pittsburgh,PA15260	25-0965591	501(c)(3)	100,000	National Glaucoma Research by Yiqin Du, MD, PhD Entitled: (G2014086)
(35) Indiana University School of Medicine 1160 West Michigan Street Indianapolis,IN46202	35-6001673	501(c)(3)	100,000	National Glaucoma Research by Lyne Racette, PhD Entitled: (G2014096)
(36) University of South Florida 4202 E Fowler Avenue Tampa,FL33620	59-3102112	501(c)(3)	100,000	National Glaucoma Research by Chris Passaglia, PhD Entitled: (G2014105)
(37) Massachusetts Eye and Ear Infirmary 243 Charles Street Boston,MA02114	04-2103591	501(c)(3)	100,000	National Glaucoma Research by Baojian Fan, MD, PhD Entitled: (G2014107)
(38) Johns Hopkins University 720 Rutland Avenue Ross 558 Baltimore,MD21205	52-0595110	501(c)(3)	100,000	National Glaucoma Research by Derek Welsbie, PhD Entitled: (G2014119)
(39) University of Colorado Eye Center 1675 Aurora Court Aurora,CO80045	84-6000555	501(c)(3)	120,000	Macular Degeneration Research by Omid Masihzadeh, PhD Entitled: (M2014014)
(40) The Schepens Eye Research Institute 20 Staniford Street Boston,MA02114	25-6638196	501(c)(3)	120,000	Macular Degeneration Research by Andrius Kazlauskas, PhD Entitled: (M2014025)
(41) Georgetown University 37th and O Streets NW Washington,DC20057	53-0196603	501(c)(3)	120,000	Macular Degeneration Research by Nady Golestaneh, MS, PhD Entitled: (M2014039)
(42) Children's Hospital Boston Harvard Medical School 300 Longwood Ave Boston,MA02115	04-2103580	501(c)(3)	120,000	Macular Degeneration Research by Michael Do, PhD Entitled: (M2014055)
(43) Tufts University 55 Kneeland Street Boston,MA02111	04-2103634	501(c)(3)	120,000	Macular Degeneration Research by Behzad Gerami-Naini, PhD Entitled: (M2014059)
(44) University of California San Francisco 3333 California Street Suite 315 San Francisco,CA94143	94-6036493	501(c)(3)	120,000	Macular Degeneration Research by Sara Venters, PhD Entitled: (M2014060)
(45) Regents of the University of Michigan 3003 South State Street Ann Arbor,MI48109	38-6006309	501(c)(3)	120,000	Macular Degeneration Research by Debra Thompson, PhD Entitled: (M2014073)
(46) The Schepens Eye Research Institute 20 Staniford St Boston,MA02114	25-6638196	501(c)(3)	120,000	Macular Degeneration Research by Neena Haider, PhD Entitled: (M2014084)
(47) University of Maryland Baltimore 620 W Lexington St 4 th Floor Baltimore,MD21201	52-6002033	501(c)(3)	120,000	Macular Degeneration Research by Richard Thompson, PhD Entitled: (M2014085)
(48) University of Illinois at Chicago 1855 W Taylor St MB 502 M/C 551 Chicago,IL60612	37-6000511	501(c)(3)	120,000	Macular Degeneration Research by David Pepperberg, PhD Entitled: (M2014091)
(49) Duke University Eye Center 106 Science Center Drive Durham,NC27705	56-0532129	501(c)(3)	120,000	Macular Degeneration Research by Priyatham Mettu, MD Entitled: (M2014099)
(50) Johns Hopkins University 720 Rutland Avenue Ross 558 Baltimore,MD21205	52-0595110	501(c)(3)	120,000	Macular Degeneration Research by Debasish Sinha, PhD Entitled: (M2014109)
(51) Massachusetts General Hospital 55 Fruit Street Boston,MA02114	04-1564655	501(c)(3)	120,000	Macular Degeneration Research by Alexander Marneros, MD, PhD Entitled: (M2014120)
(52) Wilmer Eye Institute 400 N Broadway Baltimore,MD21287	72-1483530	501(c)(3)	120,000	Macular Degeneration Research by Hu Huang, PhD Entitled: (M2014124)
(53) Wilmer Eye Institute 400 N Broadway Baltimore,MD21287	72-1483530	501(c)(3)	120,000	Macular Degeneration Research by Imran Bhutto, MD, PhD Entitled: (M2014128)
(54) Stanford University 300 Pasteur Drive Stanford,CA94305	94-1156365	501(c)(3)	120,000	Macular Degeneration Research by Douglas Vollrath, MD, PhD Entitled: (M2014137)
(55) Oklahoma University Health Sciences Center 941 Stanton L Young Blvd Oklahoma City,OK73104	73-6017987	501(c)(3)	25,400	Retinal Degeneration Meeting Grant

Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................ Bullet Image

Enter total number of other organizations listed in the line 1 table ........................ . Bullet Image

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2013

Page 2

Part III

Grants and Other Assistance to Individuals in the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a)Type of grant or assistance	(b)Number of recipients	(c)Amount of cash grant	(d)Amount of non-cash assistance	(e)Method of valuation (book, FMV, appraisal, other)	(f)Description of non-cash assistance

Part IV

Supplemental Information. Provide the information required in Part I, line 2, Part III, column (b), and any other additional information.

Return Reference

Explanation

Part I, Line 2:

BrightFocus interacts with all grantees at least quarterly by e-mail or at scientific meetings. In addition to these interactions, each grant recipient is required to submit separate detailed annual Scientific Progress and Financial Reports to BrightFocus. These are received by the BrightFocus Scientific Affairs department, and reviewed by scientific staff with broad expertise in molecular biology, cell biology, biochemistry, imaging and genetics. Senior staff reviews each Progress Report and evaluates the project for sufficient progress towards the specific aims proposed in the original application or any budgetary concerns. This effort is supported by additional scientific counsel from members of the BrightFocus Scientific Review Committees, when required. In addition to statements of experimental progress, all grantees are asked to report any technical publications, media reports, or patent applications in which BrightFocus-sponsored research is described. If significant concerns related to progress on the awards are discovered, and not resolved after interaction with the award grantee, the BrightFocus staff recommends appropriate actions to the Chair of the Board of Directors Grants Committee. The Scientific Affairs senior staff is empowered to authorize the withholding of funding, or discontinuation of awards, for any grantees that fail to achieve sufficient progress or fail to submit required reports. At the conclusion of the grant award period, each grantee must complete and submit a Final Report that is also reviewed by the BrightFocus senior scientific staff. Evaluation of the work of each grantee is qualitatively and quantitatively assessed through various metrics related to the impact of the grant on its targeted disease field. Such impact metrics have revealed that 95% of BrightFocus-supported research results in research publications that advance the fields served by BrightFocus. This impact is further supported by annual citation analysis that compares BrightFocus-supported works to a statistical sample of works supported by either the US Federal Government or that of other funding agencies. BrightFocus-supported publications are consistently cited at nearly twice the frequency of any other comparison group. A final example of impact assessment revealed that the successes of BrightFocus grantees continue long after the grant expires. On average, each grantee receives 2.2 additional grants for projects spawned by the BrightFocus grant. These come at values nearly 10 times the level of the initial BrightFocus investment. BrightFocus solicits feedback from its grantees, and provides an anonymous forum for collecting such information. Through the BrightFocus Foundation website and within In the Final Scientific Progress Report, there are designated sections where awardees are asked to provide feedback to the foundation. Through this mechanism, they are given the ability to anonymously provide feedback or communicate their concerns to Program Staff or the BrightFocus' Compliance Officer. Any suggestions, concerns, complaints, or positive experiences can be outlined and brought to the attention of BrightFocus in this manner, so that BrightFocus can address any areas needing improvement, reaffirm praise-worthy policies, or otherwise assess needs for programmatic change. The senior Scientific Staff present and summarize the status and progress on grants to the BrightFocus Board of Directors at each of their quarterly Board Meetings.

Schedule I (Form 990) 2013

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" to Form 990, Part IV, line 23.
SchJMediumBullet

Attach to Form 990. SchJMediumBullet

See separate instructions.
SchJMediumBullet

Information about Schedule J (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization

BrightFocus Foundation

Employer identification number

23-7337229

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed in Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes in line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain....

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked in line 1a? ..

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed in Form 990, Part VII, Section A, line 1a with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? ................

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3) and 501(c)(4) organizations only must complete lines 5-9.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 5a or 5b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ...........................

Any related organization? .........................

If "Yes," to line 6a or 6b, describe in Part III.

For persons listed in Form 990, Part VII, Section A, line 1a, did the organization provide any non-fixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Yes

Were any amounts reported in Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III .............................

If "Yes" to line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2013

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported in Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported as deferred in prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported as deferred in prior Form 990
(1)Stacy Pagos HallerPresident/CEO	(i) (ii)	300,480 0	50,000 0	1,935 0	38,250 0	33,440 0	424,105 0	0 0
(2)Donna CallisonVP, Development	(i) (ii)	170,155 0	10,000 0	1,584 0	25,601 0	15,707 0	223,047 0	0 0
(3)David F Marks CPA CMAVP, Finance & Administration	(i) (ii)	148,701 0	5,000 0	552 0	23,913 0	22,370 0	200,536 0	0 0
(4)Guy Eakin Ph DVP, Scientific Affairs	(i) (ii)	140,933 0	10,000 0	216 0	23,447 0	25,084 0	199,680 0	0 0

Schedule J (Form 990) 2013

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II.
Also complete this part for any additional information.

Return Reference

Explanation

Part I, Line 3

Before approving the compensation of the President/CEO, the Board determines the total compensation to be provided by BrightFocus to the President/CEO is reasonable in light of the position, responsibility and qualification of the position held including the result of an evaluation of prior performance for BrightFocus, if applicable. The President/CEO is evaluated annually by the Board of Directors through the use of an in-depth goal attainment structure, (developed with advice from Board Source) that includes a self assessment and a Board of Directors assessment and evaluation against set goals, outcomes and deliverables. The Board of Directors obtains and considers appropriate data, including a salary survey, which includes information compiled from the federal Form 990 of other organizations, concerning compensation paid to President/CEOs in like circumstances. In making the determination, the Board of Directors shall consider total compensation to include the salary and value of all benefits provided by BrightFocus to the individual in payment for services. At the time of the BrightFocus Board discussion and decision concerning the President/CEO's compensation, the President/CEO is not present in the meeting.

Part I, Line 7

As the President/CEO's bonus was not a fixed payment specified in her employment contract, this item has been answered 'yes' in accordance with the Internal Revenue Service instructions. However, it should be noted that her bonus was a non-fixed payment based on BrightFocus' internal procedures. The Board of Directors considers the award of a discretionary bonus each year. The determination of the bonus compensation is capped as specified in her employment contract, and if not warranted will not be awarded at all. The determination is made by the full Board upon recommendation of its Executive Committee that is responsible for the review of CEO compensation. The Committee considers a set of goals for the CEO's performance developed at the beginning of the year in consultation with the President/CEO. Each goal is evaluated at the end of the fiscal year to determine whether the goal has been met or exceeded. The Bonus is awarded based on a detailed review by the Board of whether each goal has been met or exceeded.

Schedule J (Form 990) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.
Right pointing arrow large image

Information about Schedule M (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization

BrightFocus Foundation

Employer identification number

23-7337229

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	11	28,644	FMV
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( )
26 Other ( )
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement ...

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that

it must hold for at least three years from the date of the initial contribution, and which is not required to be used

for exempt purposes for the entire holding period? ..................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any non-standard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

Yes

If "Yes," describe in Part II.

If the organization did not report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2013)

Page 2

Part II

Supplemental Information. Provide the information required by Part I, lines 30b,
32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Return Reference	Explanation
Part I, Line 32b:	As directed by the BrightFocus investment policy, BrightFccus' investment advisor sells all donated securities at fair market value when received.

Schedule M (Form 990) (2013)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Information about Schedule O (Form 990 or 990-EZ) and its instructions is at
www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public
Inspection

Name of the organization

BrightFocus Foundation

Employer identification number

23-7337229

Return Reference	Explanation
Form 990, Part III, Line 1, Description of Organization Mission:	BrightFocus Foundation seeks to save mind and sight by funding innovative research worldwide and by promoting better health through education. We focus our efforts on three incurable diseases affecting mind and sight: Alzheimer's disease, macular degeneration, and glaucoma. Collectively, one in 16 people over the age of 40 in the U.S. alone has one of these diseases. BrightFocus has a proven track record of supporting the most innovative, early-stage research seeking better understanding, treatments, or, ultimately, a cure for these diseases. Since 1973, BrightFocus has awarded more than $140 million in research grants to thousands of scientists around the world. Our research funding has led to major contributions to the understanding of these diseases and to the awarding of two Nobel prizes. BrightFocus-supported findings are consistently cited by other scientists at twice the frequency as other research findings. Our funding acts as a catalyst in early-stage research. The BrightFocus research programs are designed to provide initial funding for highly innovative experimental ideas. Due to the structured grant review and approval process, most recipients of BrightFocus funding go on to receive future grants from other sources that are 10 times larger than the original BrightFocus award. This one thousand percent return on BrightFocus investment speaks to our ability to identify promising research and spawn future scientific discoveries. It is our firm belief that having the courage to invest in innovative ideas will lead to revolutionary approaches and life-saving breakthroughs. Indisputably, the world-class research identified and supported by BrightFocus is more than promising: it is making a real contribution to revolutionary science in the fight to save mind and sight. Along with funding cutting-edge research to find cures to some of society's costliest diseases, BrightFocus also provides free educational materials and support to hundreds of thousands of patients and families affected by these diseases nationwide. BrightFocus increases public awareness of Alzheimer's, macular degeneration, and glaucoma, and communicates with elected officials about the importance of scientific research in these areas. BrightFocus' award-winning Public Service Announcements (PSA) have appeared on television, radio, and in print throughout the nation. Both Now is the Moment to Stop Alzheimer's Disease and See a Better Tomorrow powerfully seek to raise awareness and early detection, and similar messages have been delivered through donated print PSA space in airports and train stations, as well as at pharmacies and supermarkets. In Fiscal Year 2014, these PSA messages generated $17,597,705 in donated media services and garnered 1.5 billion impressions. We held three community forums on brain and eye diseases, and recently launched BrightFocus Chats, a free, interactive monthly telephone forum that brings together patients and caregivers to learn from, and ask questions of, leading researchers and specialists. We have launched the series through discussions related to macular degeneration, and hope to expand the program into other disease areas. The Chats are archived on our web site, with audio and print transcripts available in a number of accessible formats. We continue to increase our print publications, many in Spanish, that provide helpful information to patients and caregivers, and regularly unveil new video and audio resources in conjunction with allies in the medical and scientific communities. We have expanded our written content of key research findings, promoting and sharing this information through our web site and social media platforms. Capitalizing on emerging use of data visualization, our BrightFocus "Snapshot" series graphically communicates information on detection and treatment of macular degeneration and glaucoma. Through our social media and web resources, we conduct contests and promotions to increase awareness of these diseases and further share BrightFocus publications and events. For example, our Healthy Recipe Contest drew attention to the importance of preventive lifestyle choices, and through over 6,000 on-line votes in the Geoffrey Beene research challenge, we increased public exposure of the need for increased scientific research on gender differences in Alzheimer's. More specifically, each of these program areas mail awareness-raising materials to hundreds of thousands of households, with messages focusing on: -Symptom recognition and steps the public should take, such as making an appointment with the doctor if symptoms exist. -Lifestyle choices that promote good health, encouraging readers to take action to reduce the likelihood of the onset of the disease. -Research results and treatments available to address the disease. BrightFocus regularly interacts with members of the media, as well as elected officials and federal agency staff. We communicated to policymakers the results of our survey of leading researchers, showing the dire consequences of cutbacks in federal research budgets. Through media interviews and placements, as well as participation in advocacy coalitions, we help advance the cause of pioneering science and better expose BrightFocus as a resource for those struggling with, and searching for cures for, these terrible diseases.
Form 990, Part VI, Section B, line 11	A draft of the federal Form 990 shall be distributed to the Audit Committee for review prior to being submitted to the Internal Revenue Service. The draft federal Form 990 shall be distributed early enough to provide each Committee member with a reasonable amount of time for review and submission of questions or comments prior to the filing deadline. The final federal Form 990 shall be distributed to each Board member prior to being filed with the Internal Revenue Service. The draft and final Form 990 may be distributed in person, by regular mail, e-mail, or fax.
Form 990, Part VI, Section B, line 12c	BrightFocus has all employees, officers, and directors agree to the code of conduct that includes adherence to the Conflict of Interest and Implementation Policy. Each board director, officer, and employee is required annually to complete a conflict of interest disclosure statement. Employees meet annually with the BrightFocus Chief Compliance Officer to review their conflict of interest statements, and gives an annual conflict of interest compliance report to the Board Chair and Vice Chair. If a conflict is reported, it is then referred to the CEO and/or BrightFocus legal counsel and, if appropriate and necessary, then to the Board of Directors or its appointed Committee for further action. The director's and officer's statements are reviewed by the BrightFocus legal counsel. If a conflict is reported, it is then referred to the Board of Directors or its appointed Committee for further action. At the time of the BrightFocus discussion and decision concerning a conflict of interest, the conflicted party is not present in the meeting.
Form 990, Part VI, Section B, line 15a	The BrightFocus Foundation (BrightFocus) Board of Directors has overall authority and responsibility for approving the annual budget which includes compensation for all employees at every level including non-director officers. All pay adjustments are made on a yearly basis effective April 1st, the beginning of the BrightFocus fiscal year. Before approving the compensation of the CEO, the Board determines the total compensation to be provided by BrightFocus to the CEO is reasonable in light of the position, responsibility and qualification of the position held including the result of an evaluation of prior performance for BrightFocus, if applicable. The CEO is evaluated annually by the Board of Directors through the use of an in-depth goal attainment structure, (developed with advice from Board Source) that includes a self assessment and a Board of Directors assessment and evaluation against set goals, outcomes and deliverables. In addition, the Board of Directors periodically engages an outside consultant to obtain and consider appropriate data, including a salary survey, which includes information compiled from the federal Form 990 of other organizations, concerning compensation paid to CEOs in like circumstances. In making the determination, the Board of Directors shall consider total compensation to include the salary and value of all benefits provided by BrightFocus to the individual in payment for services. At the time of the BrightFocus Board discussion and decision concerning the CEO's compensation, the CEO is not present in the meeting. The Board shall set forth the basis for its decisions with respect to compensation in the minutes of the meeting at which the decisions are made, including the conclusions of the evaluation and the basis for determining that the individual's compensation was reasonable in light of the evaluation and comparability data.
Form 990, Part VI, Section C, line 19	BrightFocus makes its governing documents including its articles of incorporation and bylaws, conflict of interest policy, audited financial statements and federal Form 990 available to the public upon request. In addition, the public also has access to the annual report, the federal Form 1023, audited financial statements, the 501(c)(3) letter of determination from the Internal Revenue Service, and federal Form 990 on the BrightFocus website.
Form 990, Part XI, line 9:	Recoveries of prior year grants 136,575. Change in present value of grants 5,256.
Schedule F, Part II, Line 1, Column D:	Region: East Asia and the Pacific (D) Purpose of Grant: National Glaucoma Research by David Mackey, MD Entitled: (G2014032) Optic Nerve Structure Gene/environment Association. Investigators Summary: What genes affect the optic nerve and put it at risk of glaucoma? Knowing which gene changes increase the risk of glaucoma will enable us to diagnose people early and allow treatment to prevent blindness. We have previously measured photos of the optic nerve of 1400 20-year olds and identified genes associated with the size of the nerves. We now propose to analyze high resolution scans of the same nerves to search for new genes. Grant Awarded: $99,550. Lions Eye Institute, Nedlands, Australia. Region: Middle East and North Africa (D) Purpose of Grant: Alzheimer's Disease Reasearch by Michal Schnaider Beeri, PhD Entitled: (A2014268S) Vascular Function and Cognition in Type 2 Diabetes. Investigators Summary: The risk for cognitive impairment and Alzheimer's disease is increased in patients with Type 2 Diabetes (T2D), potentially due to impairments in the structure and function of blood vessels in the brain. Previous studies have shown that the problems of the functioning of blood vessels, which can be treated and reversed, is impaired before the structure of blood vessels becomes impaired, and that treatment of impaired blood vessel functioning may prevent impairment in its structure, which is irreversible. In this application we propose to study the role of blood vessel functioning in cognitive impairment in T2D patients and how different factors within T2D (for example glucose levels in the blood) affect this relationship. The results of this study may help develop treatments for the prevention of cognitive impairment in T2D and may help better understand factors that affect deleteriously cognition in all elderly. Grant Awarded: $250,000. Sheba Medical Center, Tel Hashomer, Israel. Region: Europe (D) Purpose of Grant: Alzheimer's Disease Reasearch by Elena Marcello, PhD Entitled: (A2014314F) Validating ADAM10 as Therapeutic Target for Dementia. Investigators Summary: Alzheimer's disease affects a number of elderly people, who lose their memory and their ability to take care of themselves. Such disease is caused by a substance that kills neurons. Our work is intended to develop a drug able to promote a pathway in the cell that limits the formation of this substance. We hope that our results will contribute to help people suffering of Alzheimer's disease to recover their memory. Grant Awarded: $120,000. University of Milan, Italy
Schedule F, Part II, Line 1, Column D:	Region: Europe (D) Purpose of Grant: Alzheimer's Disease Research by Enrico Glaab, PhD Entitled: Age-Related Gender Differences in brain expression Levels of Tau-Interacting Ubiquitin-specific Peptidase 9 and possible implications for Alzheimer's Disease. Grant Awarded: $50,000. University of Luxemburg, Luxemburg. Region: Europe (D) Purpose of Grant: Alzheimer's Disease Research by Rik Ossenkoppele, PhD Entitled: (A2014083F) Tau, AB and Network Degeneration in Alzheimer's Disease. Investigators Summary: Alzheimer's disease is characterized by the protein amyloid-beta that emerges 15 years before symptom onset, but its working mechanisms are not clear. Animal and post-mortem studies suggest that tau proteins may be the missing link between amyloid-beta and clinical symptoms, and since very recently, this protein can be visualized in the living human brain using positron emission tomography (PET) scans. We propose to study the role of tau in Alzheimer's disease patients by investigating its relationships with amyloid-beta, shrinkage of the brain and communication between brain cells. This study will lead to better understanding of the disease and could stimulate development of novel therapeutic agents to prevent or slow-down the devastating effects of Alzheimer's disease. Grant Awarded: $120,000. Alzheimer Center of the VU University Medical Center, Amsterdam, Netherlands. Region: Europe (D) Purpose of Grant: Alzheimer's Disease Research by Carlos Saura, PhD Entitled: (A2014417S) Transcriptional Mechanisms of Memory Loss in Alzheimer's Disease. Investigators Summary: Memory impairment is one of the earliest clinical features of AD, but the cellular events that cause brain dysfunction and memory loss are largely unclear. Memory processing depends on activation of gene expression programs in specific memory neuronal circuits. In this project, we will study the transcriptional mechanisms of gene regulation underlying memory processing in normal and AD pathology conditions. This information will be valuable to understand the causes of memory circuit dysfunction and develop novel and innovative therapies for the treatment of memory loss in AD. Grant Awarded: $249,000. Universitat Autonoma de Barcelona, Bellaterra, Spain.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: Boston University (H) Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Benjamin Wolozin, MD, PhD Entitled: (A2012054) RNA Binding Proteins in Alzheimer's Disease. Name of organization or government: University of Pennsylvania School of Medicine (H) Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Jing Guo, PhD Entitled: (A2014005F) Mouse Model for Sporadic Tauopathies. Investigator's Summary: Accumulation of misfolded tau protein in neurons is a hallmark lesion of Alzheimer's disease and many other neurodegenerative diseases. Recent studies have demonstrated that misfolded tau can spread from one cell to another and corrupt the folding of normal tau in healthy cells. We will utilize this mechanism to create a mouse model mimicking sporadically-occurring neurodegenerative diseases with tau aggregation. We will also explore the existence of distinct forms of pathological tau in different diseases. Name of organization or government: University of Rochester Medical Center (H) Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Gail Johnson, PhD Entitled: (A2014018S) Nrf2 Regulates Tau Clearance: an AD Treatment Strategy. Investigator's Summary: This focus of this study is to determine how brain cells get rid of excess tau protein. This is important because in Alzheimer disease there is a buildup of tau protein and this contributes to the ill health and eventual death of the nerve cell. We are focused on a particular system that identifies proteins that are no longer needed and engulfs and digests them. This system is called "autophagy" and in Alzheimer disease brain it is does not work efficiently. Therefore finding ways to make it work better and to selectively target tau for clearance could be beneficial to people who have Alzheimer disease. We have found that one way to improve the removal of tau from the neuron by autophagy is to upregulate proteins that make the process work better and directly deliver tau to the autophagy machinery. We have found that chemicals in foods like broccoli and green tea can cause increases in autophagy and decreases in the levels of tau. In this project we will determining how these types of chemicals improve the ability of nerve cells to get rid of excess or damaged tau protein. We will be doing this, using studies both in nerve cells that we grow in dishes and in mice. These studies will help us understand how a nerve cell normally gets rid of unwanted tau protein, what might be going wrong with this "disposal system" in Alzheimer disease and what we can do to make it work better.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: University of Kentucky (H) Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Harry LeVine, III, PhD Entitled: (A2014044S) AD Brain Neuronal Types Accumulating PIB-Binding Abeta. Investigator's Summary: Binding of a fluorescent form of the human-specific amyloid imaging ligand PIB will use flow cytometry to isolate synaptosomes from Alzheimer's disease brain to identify the type of nerve cell carrying the PIB binding amyloid pathology. The biochemical components of the synaptosomes will be determined by high sensitivity high resolution mass spectrometry. Comparison with synaptosomes isolated from a mouse model of Alzheimer's pathology with similar identifying neuronal markers will be used to identify candidates that could account for the lack of significant PIB binding in animal models and their failure to progress beyond very early AD stages to neuronal cell death and dementia. Future studies will investigate the manipulation of the candidates to increase PIB binding to better model the human AD phenotype. Name of organization or government: University of Florida (H) Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Yona Levites, PhD Entitled: (A2014105S) Targeting Intra vs Extracellular Tau by Recombinant Antibodies. Investigator's Summary: In our search for potential modifiers of Alzheimer's disease (AD) pathology in mouse models, we have developed a "somatic brain transgenics" paradigm, established by delivery of genes packaged into adeno-associated viral vectors and injected into the brains of newborn mice. Tau protein is known to go through abnormal phosphorylation and accumulation in AD for yet unclear reasons. Anti-tau immunotherapy has recently emerged as a promising approach to target tau, but many questions regarding the optimal form of anti-tau immunotherapy remain open. We propose to compare the ability of recombinant intracellular and extracellular antibodies to attenuate tau pathology in two mouse models. These studies will provide critical insights into i) whether targeting tau in the extracellular vs. intracellular compartment is more efficacious and ii) whether full length antibody and not just its binding fragment antibody effector functions are required. Name of organization or government: University of Florida (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Guilian Xu, PhD Entitled: (A2014108S) Protein Homeostasis in Mouse Models of Alzheimer Pathology. Investigator's Summary: In this proposal, we investigate fundamental changes that occur in way nerve cells manage the production of new proteins and the disposal of old proteins. This process is essential to the normal functioning of the brain. In work prior to this proposal, we have identified a new pathology associated with Alzheimer's disease that we call secondary misfolding pathology, which describes changes in the ability of nerve cells to produce functional enzymes and proteins. In this proposal we will be working to better understand how this new pathology we have discovered may be affecting the ability of brain to function.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: Mayo Clinic Jacksonville (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Mitsuru Shinohara, PhD Entitled: (A2014137F) Synaptic Regulation of AB Metabolism and Secreted Markers. Investigator's Summary: To understand why your friends or relatives develop Alzheimer's disease (so-called etiology), we need to develop bio-markers that can evaluate the disease progression as well as the underlying disease processes, especially those related to toxic AB accumulation in brains. Recent studies, including our study, demonstrate that synapses (neuronal connections in brain) play important roles in toxic AB accumulation. By elucidating how these synapses regulate the metabolism of toxic AB in brains at a molecular level and what proteins or molecules in body fluids are associated with these phenomena; this proposed research will be able to identify appropriate biomarkers that indicate disturbances in synaptic AB metabolism in brains, before the development of Alzheimer's disease. Such bio-markers would be very useful in order to identify and clarify the etiology underlying the progression of AB accumulation in individual persons, and may ultimately lead to effective treatments for Alzheimer's disease. Name of organization or government: Washington University (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Kristen Funk, PhD Entitled: (A2014164F) Differential Uptake of Tau Fibrils into Neurons and Glia. Investigator's Summary: Alzheimer's disease is defined, in part, by deposits of aggregated tau protein within neurons of affected brain. Recent data have suggested that progression of AD may be due to the release of tau aggregates from afflicted neurons, followed by the uptake of tau fibrils into naive neurons, resulting in the propagation of tau pathology. To date, the role of glia in this model has remained unexplored; however, we hypothesize that promoting uptake into glia may clear tau aggregates without contributing to disease progression. Studies proposed here will establish the mechanisms of tau uptake that differ between neurons and glia with the goal to identify potential therapeutic targets that block uptake into neurons while promoting uptake into glia. Name of organization or government: Columbia University Medical Center (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Tal Nuriel, PhD Entitled: (A2014200F) Metabolomic/Lipidomic Analysis of ApoE Isoform Effects. Investigator's Summary: Carriers of the APOE e4 gene are at significantly increased risk for developing Alzheimer's disease. In order to understand the cause of this increased Alzheimer's risk, we will utilize emerging technology to measure the levels of lipids and small-molecules in mouse and human brain tissues possessing differing forms of APOE. We anticipate that the results of this study will shed new light on why carriers of the APOE e4 gene are more susceptible to Alzheimer's disease and how Alzheimer's disease can be prevented in these individuals.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: University of Kentucky (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Steven Estus, PhD Entitled: (A2014210S) Genomic Editing to Elucidate CD33 Function. Investigator's Summary: About 70% of Alzheimer's disease risk is due to differences in DNA sequences between people. Here, we have identified how one of these DNA sequence variations changes gene expression to reduce Alzheimer's risk. The action of the DNA sequence difference is a modest 15% decrease in functional gene expression. Remarkably, an inhibitor of this gene has already been in clinical trials for leukemia, and will be tested here for its ability to act similarly to the DNA sequence variation. Name of organization or government: University of Washington School of Medicine (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Richard Morrison, PhD Entitled: (A2014237S) Bif-1 Therapy for Cognitive Impairment and Neuropathology in AD. Investigator's Summary: We have identified a protein with a unique protective function in nerve cells and this protein is lost in the brains of patients with Alzheimer's disease. The loss of this protein may make the disease worse based on studies we've done where we eliminate the protein in mice that also express symptoms of Alzheimer's disease. We would like to determine if we can improve cognitive function in patients with Alzheimer's disease by restoring the expression of this protein. We will test this possibility by developing a method to restore this protein in the nerve cells of mice that also express symptoms of Alzheimer's disease and we will determine if their cognitive abilities improve. Name of organization or government: Washington University (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by David Brody, MD, PhD Entitled: (A2014270S) Purification and Characterization of Amyloid-beta Oligomers from Human Brain. Investigator's Summary: Alzheimer's disease is the most common cause of problems with memory, thinking, and behavior in older people; it is most likely caused by accumulation of a small protein called amyloid-beta. There is no cure or effective treatment for Alzheimer's disease despite decades of work, in part because our attempts so far have not focused on the most toxic forms of amyloid-beta. We have developed methods to accurately measure these toxic forms of amyloid-beta in the brains of Alzheimer's disease patients, and we now propose to purify them so that we can study them in detail. This project is vital because understanding the toxic forms of amyloid-beta will help us efficiently design effective treatments to prevent them from forming, block their toxicity, or destroy them.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: University of Kentucky (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by M. Paul Murphy, MA, PhD Entitled: (A2014280S) A Novel Therapy for the Treatment of Dementia. Investigator's Summary: We are going to use a unique mouse model that we have developed (the db/AD mouse) to test a potential treatment for Alzheimer's disease (AD). Many cases of AD are also accompanied by large amounts of vascular pathology in the brain. The mouse we have developed has cognitive deficits reflective of the deficits seen in AD, and the db/AD mice also experience aneurysms and strokes which indicate the presence of vascular disturbances in the brain. In the hopes of improving the vascular pathology, we are going to treat these mice with a drug that is already approved for human use, and we will perform MRI imaging at regular time points to monitor any effect the drug treatment has on the vascular pathology in the brain. Name of organization or government: Washington University (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Richard Perrin, MD, PhD Entitled: (A2014296S) Novel CSF Biomarkers in Familial Alzheimer Disease. Investigator's Summary: The goal of this study is to discover a timeline of protein changes within the cerebrospinal fluid (the fluid that bathes the brain) that can be used to diagnose and monitor Alzheimer's disease (AD), even years before symptoms of the disease appear. To accomplish this goal, we will apply a powerful new technique (quantitative label-free proteomics) to measure hundreds of proteins in cerebrospinal fluid samples from people enrolled in the Dominantly Inherited Alzheimer Network (DIAN) study. Familial AD is uniquely suited to this mapping study of very early changes because the age at which symptoms begin can be reliably predicted from affected family members, and diagnosis can be definitively established by genetic testing even decades before symptoms are predicted. Such a timeline will improve the accuracy of early diagnosis, maximize the efficiency of clinical trials, and move effective treatments more quickly and cheaply from the laboratory to the pharmacy. Name of organization or government: The Ohio State University (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Chien-liang Lin, PhD Entitled: (A2014315S) Regulating Glutamate Levels as a Therapeutic Strategy for Alzheimer's Disease. Investigator's Summary: The glial glutamate transporter EAAT2 is responsible for maintaining low extracellular glutamate concentrations in our brains. Loss of EAAT2 protein and function is commonly found in patients with Alzheimer's disease. We discovered that restoration of EAAT2 function can reverse Alzheimer phenotypes in an animal model of Alzheimer's disease. The goal of this research is to develop restoration of EAAT2 function as a therapeutic strategy for Alzheimer's disease.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: University of Chicago (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Virginie Buggia-Prevot, PhD Entitled: (A2014316F) Role of EHD Proteins in Alzheimer's Disease Pathogenesis. Investigator's Summary: The goal of my research is to better understand the causes of Alzheimer's disease by studying the mechanisms that contribute to the disease apparition, in order to identify potential therapeutic targets. In the brain of individuals with Alzheimer's disease, a toxic peptide called amyloid is overproduced and leads to dysfunction of memory functions and ultimately the death of the nerve cells. I recently found two proteins called EHD, which are involved in amyloid peptide production in cultured neurons. The proposed investigation would determine if there is an alteration of EHD in human brains that could facilitate amyloid overproduction, and to test if amyloid overproduction could be blocked by abolishing the expression of EHD in mice that are engineered to develop Alzheimer's Disease pathology. Thus, the proposal investigates neuronal mechanisms that are intimately associated with Alzheimer's disease with the goal of establishing EHD proteins as one of the molecular players in disease pathogenesis. Name of organization or government: Northwestern University (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Jian Li, PhD Entitled: (A2014349F) Stress Response Networks in Organismal Proteostasis. Investigator's Summary: Alzheimer's disease patients are featured with aggregation of abnormally folded beta amyloid proteins in the brain that interfere with the cellular functions and eventually lead to degeneration of neurons. Stress response factors have been suggested to protect the protein toxicity associated with Alzheimer's disease. This protection could occur both in the beta amyloid expressed tissue and the neighboring tissues. Here we set out to characterize the protective mechanisms mediated by stress response pathways especially how neurons sense the toxic aggregation and how they communicate with neighboring tissues to end up an organismal protection. Name of organization or government: Washington University (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Randall Bateman, MD Entitled: (A2014384S) Stable Isotope Labeling Kinetics of Human TAU In Alzheimer's Disease. Investigator's Summary: In Alzheimer's disease Tau is increased in the brain and fluid that surrounds the brain. It is unclear why it is increased. Is this due to increased production or impaired clearance? How much is production or clearance altered? Can drugs be developed that can correct abnormal tau production or clearance? These questions can now be answered and give drugs which target tau a better chance of working in Alzheimer's disease.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: University of South Dakota (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Hongmin Wang, PhD Entitled: (A2014420S) Using Mouse Models to Study the Role of Ubiquilin-1 in Alzheimer's Disease. Investigator's Summary: A protein named ubiquilin-1, has long been considered to play a role in Alzheimer's disease. However, the exact role of the protein in Alzheimer's disease remains unclear. This research project is to investigate whether increase or depletion of ubiquilin-1 protein in genetically modified mice changes the signs and conditions of Alzheimer's disease. Name of organization or government: Stanford University (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Katrin Andreasson, MD Entitled: (A2014423S) Inhibiting Tryptophan Metabolism in Alzheimer's Disease. Investigator's Summary: The proposed work will determine whether degradation of the amino acid tryptophan by the enzymes TDO2 and IDO1 functions in development of Alzheimer's disease. We will use genetic and pharmacologic approaches in a mouse model of AD to identify mechanisms of action of these enzymes in early and late stages of AD development. Successful completion of these studies may lead to a novel preventive and therapeutic strategies to delay onset of AD in at-risk aging populations. Name of organization or government: Columbia University Medical Center (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Alice Lepelley, PhD Entitled: (A2014425F) Implication of a Mitochondrial Protein, ECSIT, in the Oxidative Stress Leading to Alzheimer's Disease. Investigator's Summary: Alzheimer's Disease is the world's most common cause of dementia and oxidative stress has emerged as a key feature and possible cause of the disease. It appears early and can accelerate progression of the disease. However, only a few treatments trying to prevent oxidative stress have provided positive results. With this project we will study a promising novel mechanism causing oxidative stress in hope to provide ideas for more efficient therapeutics.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: Seattle Institute for Biomedical and Clinical Research (H) Purpose of Grant or Assistance: Alzheimer's Disease Research by Brian Kraemer, PhD Entitled: (A2014438S) Dopamine Signaling Controls Pathological Tau. Investigator's Summary: A number of neurodegenerative disorders have tau deposits including Alzheimer's disease. Abnormal tau protein can cause age dependent neurodegeneration in Alzheimer's disease and related disorders. We have identified a class of drugs that prevent abnormal tau formation in animal models of disease. The goal of this project is to understand how these drugs prevent abnormal tau so we can develop these drugs further ultimately setting the stage for clinical trials in Alzheimer's patients. Name of organization or government: University of California, San Francisco (H) Purpose of Grant or Assistance: National Glaucoma Research by Jeffrey L Goldberg, MD, PhD Entitled: (C2015200) Early Phase Testing of Regenerative Therapies in Glaucoma. Name of organization or government: University of California, San Francisco (H) Purpose of Grant or Assistance: National Glaucoma Research by Douglas Gould, PhD Entitled: (G2014007) Identification and in Vivo Balidation of Novel Genes for Developmental Glaucoma. Investigator's Summary: Anterior segment dysgenesis (ASD) describes problems affecting the front part of the eye. One of the major consequences of ASD is glaucoma which can lead to irreversible blindness at a young age. Our goal is to understand how these problems come about with the end goal of establishing treatments.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: Washington University (H) Purpose of Grant or Assistance: National Glaucoma Research by Jeff Gidday, PhD Entitled: (G2014012) Hypoxic Conditioning for Protection in DBA/2J Glaucoma. Investigator's Summary: A fundamental principle of biology (and evolution) is that organisms, and cells, adapt to a stress imposed on them so that they can better handle that stress if encountered again in the future. The studies in this research project are designed to leverage this concept as a way of protecting the eye from glaucoma. In particular, we will test whether intermittently exposing mice to a hypoxic or low-oxygen stress, that by itself is not harmful; will trigger adaptive responses in the eye that make it more resistant to the damaging effects of glaucoma. If successful, these studies will confirm the presence of innate protective responses in the eye that someday could be activated in humans with glaucoma, thereby reducing the vision loss and blindness that characterizes this devastating disease. Name of organization or government: University of Wisconsin (H) Purpose of Grant or Assistance: National Glaucoma Research by Donna Peters, PhD Entitled: (G2014051) Use of Small Molecules to Control ECM Homeostasis. Investigator's Summary: A major risk factor for glaucoma is an elevation of intraocular pressure caused by the reduced movement of fluid out of the eye. This movement is restricted because the passageways that allow fluid to exit the eye are clogged with too much protein. The goals of this research are to understand how these proteins are deposited in these passageways and to identify ways to prevent the proteins from being deposited. Name of organization or government: Oregon Health and Science University (H) Purpose of Grant or Assistance: National Glaucoma Research by Janice Vranka, PhD Entitled: (G2014058) Altered Versican Fibrillar Interactions in the Outflow Pathway. Investigator's Summary: Our research focuses on the trabecular meshwork, a discrete tissue located in the eye around the base of the cornea, near the ciliary body, which is responsible for draining the aqueous humor from the eye via the anterior chamber and is believed to be the tissue that regulates intraocular pressure, a critical factor in the development of glaucoma. Our laboratory is investigating the hypothesis that a specific subset of complex molecules that reside in the trabecular meshwork, and that interact with each other, are important in the regulation of aqueous humor outflow resistance. When these processes are disrupted there will be changes in the tissue that lead to alterations in outflow facility. Thus our primary objective is aimed at improving the overall understanding of how aqueous humor outflow resistance is regulated and what are the triggers in the development of glaucoma in order to facilitate the development of novel therapies aimed at helping glaucoma patients.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: Legacy Health System (H) Purpose of Grant or Assistance: National Glaucoma Research by Lin Wang, MD, PhD Entitled: (G2014059) Glia-mediated Blood Flow Autoregulation in Glaucoma. Investigator's Summary: Glaucoma is the second most common cause of blindness worldwide. Studies over the past few years have shown that blood flow and the way it changes in the diseased eye play a role. This project will look at what causes the blood flow change and this could lead to an original treatment for this disease. Name of organization or government: University of North Texas Health Science Center (H) Purpose of Grant or Assistance: National Glaucoma Research by Colleen McDowell, PhD Entitled: (G2014063) Crosstalk of TGF-beta and TLR4 pathways in the trabecular meshwork. Investigator's Summary: One of the major risk factors for the development of glaucoma is an increased pressure inside the eye. An increase of pressure occurs in the eye when fluid is not drained properly through the drainage structures in the front of the eye. Our project aims to understand what regulates the arrangement and construction of the drainage structures and how changes in this makeup prevent proper drainage in the eye. Name of organization or government: University of Nebraska Medical Center (H) Purpose of Grant or Assistance: National Glaucoma Research by Dhirendra Singh, PhD Entitled: (G2014067) Oxidative Stress and Sumoylation in Pathobiology of Trabecular Meshwork. Investigator's Summary: Glaucoma is related to overstimulation of certain genes/proteins in the trabecular meshwork (TM), a condition caused by reduced expression of antioxidants which results from aging or oxidative stress. We propose to examine further the underlying causes and mechanisms by which pathobiology of the TM develops, and explore novel targets for glaucoma therapy, including antioxidant therapy based on the protective protein Prdx6.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: Duke University Eye Center (H) Purpose of Grant or Assistance: National Glaucoma Research by Stuart McKinnon, MD, PhD Entitled: (G2014076) Neuroinflammation: the Role of Lymphocytes in Glaucoma. Investigator's Summary: In glaucoma, permanent vision loss and blindness occur when retinal ganglion cells (RGCs) that make up the optic nerve are lost. Increasing evidence points to a central role of the immune system in the death of RGCs in glaucoma. We have recently shown the surprising finding that in an experimental mouse model of glaucoma, a severely immunodeficient transgenic mouse that lacks T- and B-lymphocytes (Rag1 knockout) is robustly protected against optic nerve damage due to chronic exposure to elevated intraocular pressure (IOP). These transgenic mice lack expression of Rag1, a protein essential to the generation of mature T- and B-lymphocytes, and are thus immunodeficient. This finding generates the novel hypothesis that immune system events involving lymphocytes are necessary for RGC cell death and optic nerve axon loss in glaucoma. This project will determine whether specific populations of lymphocytes are required for RGC death in glaucoma, and to determine if blocking lymphocyte extravasation into ocular tissues (diapedesis) rescues RGCs in a mouse glaucoma model. We will isolate T- or B-cells using standard immunology techniques and transfer these cells to Rag1 knockout mice to reconstitute this portion of the mouse immune system. We will then utilize our well-established mouse glaucoma model to determine if either T- or B-cells are necessary for RGC axon loss. Lymphocytes migrate from the bloodstream to tissues by the process of diapedesis, which requires the expression of a4 integrin protein on vascular endothelium. We will induce glaucoma in transgenic mice that carry a point mutation in a4 integrin to determine if blocking lymphocyte diapedesis is neuroprotective in our mouse glaucoma model. We will also test whether pharmacological blockage of a4 integrin-mediated diapedesis with a murine version of natalizumab (Tysabri, Biogen, Inc.) is neuroprotective in our mouse glaucoma model. If T- or B-cells are necessary for glaucoma damage, further research will be designed to determine whether specific lymphocyte subpopulations (e.g. CD4+, CD8+, etc.) can be identified as crucial to RGC axon loss in glaucoma. Given the existing literature, data supporting or refuting the roles of lymphocytes in glaucomatous RGC death would represent a significant advance for the field and therapies can be designed to modulate the immune system and prevent vision loss and blindness in our human glaucoma patients. Name of organization or government: University of Pittsburgh (H) Purpose of Grant or Assistance: National Glaucoma Research by Yiqin Du, MD, PhD Entitled: (G2014086) A Mouse Glaucoma Model and Stem Cell-Based Therapy for Glaucoma. Investigator's Summary: Glaucoma is a leading cause of irreversible blindness; elevated intraocular pressure is a major risk factor and it is controllable. The trabecular meshwork acts as a drainage system to the eye, and blockage of this drainage, such as by irregularities in the cells and matrix of the meshwork, can lead to a build-up of aqueous fluid in the eye and subsequent elevation of intraocular pressure. We have isolated and characterized immature stem cells from the trabecular meshwork with the ability to seek out and repair the damage in this tissue. This project will identify a drug enabling us to model elevated pressure by damaging trabecular meshwork in a mouse, then to apply trabecular meshwork stem cells with the purpose of restoring a functioning meshwork and reducing the intraocular pressure. Name of organization or government: Indiana University School of Medicine (H) Purpose of Grant or Assistance: National Glaucoma Research by Lyne Racette, PhD Entitled: (G2014096) An Individualized Model to Monitor Laucoma Progression. Investigator's Summary: Glaucoma is an eye disease that can lead to blindness. We propose a new model to detect glaucoma changes over time. This model will be tailored for each patient and tested in a different group of patients. We will use this model to predict which patients are likely to change over time.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: University of South Florida (H) Purpose of Grant or Assistance: National Glaucoma Research by Chris Passaglia, PhD Entitled: (G2014105) An Implantable System for Intraocular Pressure Measurement and Control. Investigator's Summary: To understand the causes and effects of glaucoma, researchers often rely on animal models in which eye pressure is elevated by experimental means. Traditional methods of elevating pressure can reproduce key features of the disease, but they are limited by finite success rates, sporadic pressure information, and variable exposure histories. These limitations hamper research progress and may prevent major breakthroughs. The overarching goal of this project to develop a smart pump that would for the first time gives glaucoma researchers and clinicians unprecedented control over eye pressure. Name of organization or government: Massachusetts Eye and Ear Infirmary (H) Purpose of Grant or Assistance: National Glaucoma Research by Baojian Fan, MD, PhD Entitled: (G2014107) Discovery of PDS/PG Genes by Exome Sequencing. Investigator's Summary: Pigment dispersion syndrome (PDS) causes pigmentary glaucoma which is a common form of open-angle glaucoma that usually affects young adults and can be inherited. No genes responsible for this condition have been identified so far in humans. In this proposal, we will use whole exome sequencing, a new and powerful technology to find genes that can cause this common form of glaucoma. The results from this project can be used to develop new methods of diagnosis and treatment for PDS and pigmentary glaucoma. Name of organization or government: Johns Hopkins University (H) Purpose of Grant or Assistance: National Glaucoma Research by Derek Welsbie, PhD Entitled: (G2014119) Developing Dual Leucine Zipper Kinase Inhibitors for Glaucoma. Investigator's Summary: Nerve cells called retinal ganglion cells from the connection between the eye and the brain. In glaucoma, these nerve cells die and vision is permanently lost. We have previously shown that a protein called dual leucine zipper kinase (DLK) is critical for the death of these cells. Thus, this proposal seeks to identify a drug that might block interfere with DLK and prevent retinal ganglion cell death.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: University of Colorado Eye Center (H) Purpose of Grant or Assistance: Macular Degeneration Research by Omid Masihzadeh, PhD Entitled: (M2014014) Simultaneous, Structural And Functional Imaging Of The Retinal Pigment Epithelium. Investigator's Summary: Progression of age-related macular degeneration (AMD) coincides with structural changes to the eye. Currently, clinicians and researches use visible light and histological sectioning to study these changes, but are limited to detections of only fairly large structures and lack necessary information associated with the disease. We propose a new paradigm in light microscopy to detect both structures changes and functional abnormalities associated with AMD. Currently, this detection method is unknown and unavailable to researchers and clinicians. We propose to investigate the viability of this technique for studying AMD. Name of organization or government: The Schepens Eye Research Institute (H) Purpose of Grant or Assistance: Macular Degeneration Research by Andrius Kazlauskas, PhD Entitled: (M2014025) HtrA1 is required for RPE Survival During ER Stress. Investigator's Summary: In aging patients with central vision loss, a group of cells in the back of the eye, retinal pigment epithelia (RPE) is specifically injured. The aim of this study is to examine whether RPE injury arises from sustained, irreparable damage to the cell's protein factories. We predict that patients with changes to a protein called HtrA1 are particularly prone to such damages. We propose that rectifying RPE injury with "chemical chaperones" can benefit these patients, and that this class of drugs can be used as a strategy to manage central vision loss. Name of organization or government: Georgetown University (H) Purpose of Grant or Assistance: Macular Degeneration Research by Nady Golestaneh, MS, PhD Entitled: (M2014039) Autophagy, a Critical Pathway in the Pathophysiology of Age-related Macular Degeneration. Investigator's Summary: Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly. More than 11 million Americans are affected by AMD with no effective treatments available. Autophagy is a self-eating process in the cells that involves degradation of unwanted cellular components to supply the cell with energy when needed. Failure in autophagy is related to diseases. We propose to study the role of autophagy and its possible dysfunction in AMD.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: Children's Hospital Boston, Harvard Medical School (H) Purpose of Grant or Assistance: Macular Degeneration Research by Michael Do, PhD Entitled: (M2014055) Mechanisms of Signaling in the Fovea. Investigator's Summary: Few organisms have a more detailed visual experience than humans. The reason is that we possess a specialization of our retina, called the fovea, that constitutes an extraordinarily "high definition" pixel array. Macular degeneration is a leading cause of blindness that devastates vision by attacking the fovea. By investigating how the fovea works, we will help the diagnosis, prevention, and treatment of macular degeneration, while also gaining insight into how our power of sight outstrips that of most other creatures. Name of organization or government: Tufts University (H) Purpose of Grant or Assistance: Macular Degeneration Research by Behzad Gerami-Naini, PhD Entitled: (M2014059) Tissue Engineering Dental Pulp Stem Cell Derived-RPE on a Bio-mimetic Silk Membrane. Investigator's Summary: Age-related macular degeneration (AMD) is a devastating eye disease that affects a large percentage of the American population. Although we don't have a cure or a good way to restore vision in individuals affected by the disease, there are ways to prevent further vision loss for patients that are suffering from AMD. Our approach is to extract the stem cells from a patient's tooth and turn them into an important eye cell that we can then transplant back into the patient's eye. In order to transplant these eye cells, we need the cells to remain intact and will be using silk as a natural product that the body won't reject to deliver these eye cells. Name of organization or government: University of California, San Francisco (H) Purpose of Grant or Assistance: Macular Degeneration Research by Sara Venters, PhD Entitled: (M2014060) Establishing the Foveal Retina During Embryonic Development. Investigator's Summary: The central retina is the small portion of the eye used for our clearest and sharpest vision. Anatomically, it is different from the rest of the eye, and we do not understand exactly why. The central retina is specifically affected in several eye diseases, and trying to understand how exactly it differs can help with treatment and future therapies for re-growing this portion. In this proposal we will first follow the development of the precursors to the central retina, and next we will determine which, if any, of the environments that they pass through during development is important for making them specifically central retina.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: Regents of the University of Michigan (H) Purpose of Grant or Assistance: Macular Degeneration Research by Debra Thompson, PhD Entitled: (M2014073) Control of Innate Inflammatory Responses in the Retina. Investigator's Summary: One aspect of the damage to the retina that occurs in age-related macular degeneration (AMD), a disease responsible for visual handicap in millions of elderly people, is caused by the presence of low grade inflammation over long periods of time. Specialized cells in the retina express a class of cell-surface proteins that are known to play a role in opposing inflammatory responses in other tissues of the body. The purpose of the proposed studies is to determine the role of these proteins in decreasing inflammatory responses in the retina. The outcome of these studies will lead to increased understanding of the control inflammation in the retina, and the possibilities for developing novel therapies aimed at regulating this mechanism. Name of organization or government: The Schepens Eye Research Institute (H) Purpose of Grant or Assistance: Macular Degeneration Research by Neena Haider, PhD Entitled: (M2014084) Novel Genetic Model of Choroidal Neovascular Age-related Macular Degeneration. Investigator's Summary: Age related macular degeneration (AMD) is easily becoming the number one cause of blindness in the world today. A major problem in finding a cure is not knowing what causes the disease and having a good model system to test a therapy. In this study, we utilize a novel genetic model that recapitulates the blood vessel defect seen in AMD patients and thus have a powerful tool to identify a factor that can cause this disease outcome, understand the disease process, and a model to test therapies. Name of organization or government: University of Maryland, Baltimore (H) Purpose of Grant or Assistance: Macular Degeneration Research by Richard Thompson, PhD Entitled: (M2014085) Role of Zn and HAP in Inducing Sub-RPE Deposits and Age-related Macular Degeneration. Investigator's Summary: We have discovered what appears to be an early step in the process of developing deposits (drusen) in the aging retina, which can lead to macular degeneration (AMD). We believe that zinc and inflammation are involved, and have developed a method for visualizing when the step has occurred in the intact eye. The thrust of our project is to see how zinc and inflammation are involved in this step and how early and broadly the step may occur in ordinary eyes: does the step happen at 40 years of age, at 60 years of age, and does it occur in everybody? We anticipate our visualization method may be usable as a screening test for AMD (patent pending), and our improved understanding of how AMD develops may lead to new, early treatments.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: University of Illinois at Chicago (H) Purpose of Grant or Assistance: Macular Degeneration Research by David Pepperberg, PhD Entitled: (M2014091) Exogenous Peptidase for Amyloid-beta Degradation. Investigator's Summary: Current knowledge suggests that the development of age-related macular degeneration (AMD), a blinding disease that affects many older individuals, may involve the abnormally high build-up of a protein known as "amyloid-beta" in the eye. If abnormally high amyloid-beta indeed promotes AMD, removing this excessive amyloid-beta could be a therapy for AMD. It is known that a type of enzyme termed "peptidase" can break down amyloid-beta. Accordingly, using mice with AMD-like disease as our experimental system, we propose to study whether artificially increasing the amount of peptidase in the eye can slow or block the progress of the disease. Name of organization or government: Duke University Eye Center (H) Purpose of Grant or Assistance: Macular Degeneration Research by Priyatham Mettu, MD Entitled: (M2014099) Macrophages Drive Neovascular Remodeling in NV Age-related Macular Degeneration. Investigator's Summary: Our research is trying to understand what causes the severe form of wet macular degeneration, a common disease of the back of the eye (retina) and one of the leading causes of blindness in the United States. Macrophages are cells in the body that fight off infection, but in some cases, can cause damage to tissues in the body. We are trying to determine how macrophages make wet macular degeneration worse and harder to treat with available medicines. If we can understand how macrophages make this disease worse, we hope that we can develop new medicines to treat patients with the disease who continue to lose vision. Name of organization or government: Johns Hopkins University (H) Purpose of Grant or Assistance: Macular Degeneration Research by Debasish Sinha, PhD Entitled: (M2014109) Understanding How Dysregulation of Autophagy/phagocytosis activates the Immune System in RPE Cells, Leading to Age-related Macular Degeneration-like Pathology. Investigator's Summary: The Retinal Pigmented Epithelium (RPE) is a single layer of pigmented cells situated between the neurosensory retina and the choroid, the vascular layer at the back of the eye. The RPE is involved in the phagocytosis of photoreceptor outer segments (OS), a role essential for the maintenance and survival of the photoreceptors (light sensitive cells) as well as autophagy (self digestion by a cell), and may be of particular importance because of the very high metabolic activity of RPE. We have generated a RPE-specific Cryba1 gene knockout mouse, which will serve as a genetic tool to better understand the processes of phagocytosis and autophagy in RPE. Our studies may lead to development of therapeutic targets in the future for some manifestations of AMD that result from defective phagocytosis and/or autophagy in RPE.
Schedule I, Part II, Line 1, Column (H):	Name of organization or government: Massachusetts General Hospital (H) Purpose of Grant or Assistance: Macular Degeneration Research by Alexander Marneros, MD, PhD Entitled: (M2014120) Inflammasome regulation in age-related Macular Degeneration. Investigator's Summary: Age-related macular degeneration (AMD) is the most common cause of irreversible blindness in the elderly and is caused by a local inflammatory response affecting the function of the retinal pigment epithelium and the photoreceptors. In a mouse model of AMD we could show that inhibiting a molecular complex that is important for propagating this inflammatory response, the inflammasome, reduces pathologies of AMD in this model. Thus, we propose that mechanisms that inhibit the inflammasome are likely to reduce AMD progression in patients as well. Here, we will test mechanisms that control inflammasome activation in a mouse model of AMD to identify potential novel treatment approaches for AMD. Name of organization or government: Wilmer Eye Institute (H) Purpose of Grant or Assistance: Macular Degeneration Research by Hu Huang, PhD Entitled: (M2014124) Mechanisms by Cxcr5 Regulates Pathogenesis of Macular Degeneration. Investigator's Summary: I have recently found that a new gene is potentially involved in the disease of age-related macular degeneration (AMD). Without this gene, the aged mice develop a number of anomalies that resemble AMD pathologies. So this proposed research is to determine if this gene is involved in AMD progression. Name of organization or government: Wilmer Eye Institute (H) Purpose of Grant or Assistance: Macular Degeneration Research by Imran Bhutto, MD, PhD Entitled: (M2014128) The Inflammatory Cells of Choroid in Age-related Macular Degeneration. Investigator's Summary: Macular degeneration is a progressive eye condition affecting as many as 15 million Americans. The disease attacks the macula of the eye, where our sharpest central vision occurs, affecting reading, driving, identifying faces, watching television, safely navigating stairs and performing other daily tasks. The retinal pigment epithelium and choriocapillaris, the blood vessels that provide nutrition to the outer retina, die in age-related macular degeneration (AMD). This study will document the inflammatory cells under retina that may contribute to this death if activated. Drugs already exist to control their activation so this study could suggest new therapies for AMD. Name of organization or government: Stanford University (H) Purpose of Grant or Assistance: Macular Degeneration Research by Douglas Vollrath, MD, PhD Entitled: (M2014137) Genetics of RPE Metabolism: Implications for Age-related Macular Degeneration. Investigator's Summary: The nerves that sense light in the eye and the cells of the retinal pigment epithelium (RPE) form a critical partnership necessary for vision. We seek to understand how the capability of RPE cells to get energy from food molecules varies among human individuals due to differences in their genes and how RPE cells control this process. Success of this project may help us to better understand why macular degeneration affects some people more than others, eventually leading to improved treatment for this disease.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990 or 990-EZ) 2013

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
MediumBullet

Attach to Form 990. MediumBullet

See separate instructions.
MediumBullet

Information about Schedule R (Form 990) and its instructions is at www.irs.gov/form990.

OMB No. 1545-0047

2013

Open to Public Inspection

Name of the organization

BrightFocus Foundation

Employer identification number

23-7337229

Part I

Identification of Disregarded Entities Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
(1) National Development LLC 22512 Gateway Center Drive Clarksburg,MD20871 23-7337229	Property rental and management	MD	566,205	4,792,949	N/A
(2) American Health Assistance LLC 22512 Gateway Center Drive Clarksburg,MD20871 23-7337229	Owner of BrightFocus headquarters	MD	0	4,162,074	N/A

Part II

Identification of Related Tax-Exempt Organizations Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2013

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(i) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	Yes	No

Schedule R (Form 990) 2013

Page 3

Part V

Transactions With Related Organizations Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest (ii) annuities (iii) royalties or (iv) rent from a controlled entity . . . . . . . . . . . . . . . . . . . . . . .

b Gift, grant, or capital contribution to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

c Gift, grant, or capital contribution from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

d Loans or loan guarantees to or for related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

e Loans or loan guarantees by related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

f Dividends from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

g Sale of assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

h Purchase of assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

i Exchange of assets with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

j Lease of facilities, equipment, or other assets to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . .

k Lease of facilities, equipment, or other assets from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . .

l Performance of services or membership or fundraising solicitations for related organization(s) . . . . . . . . . . . . . . . . . . . .

m Performance of services or membership or fundraising solicitations by related organization(s) . . . . . . . . . . . . . . . . . . . .

n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) . . . . . . . . . . . . . . . . . . . . .

o Sharing of paid employees with related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

p Reimbursement paid to related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

q Reimbursement paid by related organization(s) for expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

r Other transfer of cash or property to related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

s Other transfer of cash or property from related organization(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved

Schedule R (Form 990) 2013

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(e) Are all partners section 501(c)(3) organizations?		(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V?UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V?UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No

Schedule R (Form 990) 2013

Page 5

Part VII

Supplemental Information

Provide additional information for responses to questions on Schedule R (see instructions).

Return Reference	Explanation

Schedule R (Form 990) 2013

Additional Data

Software ID:
Software Version:

1	Briefly describe the organization’s mission or most significant activities: BrightFocus Foundation seeks to save sight and mind.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	11
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	11
5	Total number of individuals employed in calendar year 2013 (Part V, line 2a) ......	5	51
6	Total number of volunteers (estimate if necessary) .............	6	96
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	0
b	Net unrelated business taxable income from Form 990-T, line 34 .........	7b	0

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	23,534,029	25,126,233
9	Program service revenue (Part VIII, line 2g) .........	0	0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	614,981	766,939
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	734,020	830,470
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)...................	24,883,030	26,723,642
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	7,527,500	8,755,315
14	Benefits paid to or for members (Part IX, column (A), line 4).....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	3,758,245	4,031,826
16a	Professional fundraising fees (Part IX, column (A), line 11e).....	512,040	407,033
b	Total fundraising expenses (Part IX, column (D), line 25) 4,854,132
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	11,776,521	11,933,206
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	23,574,306	25,127,380
19	Revenue less expenses. Subtract line 18 from line 12.......	1,308,724	1,596,262
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	42,238,889	48,181,675
21	Total liabilities (Part X, line 26).............	14,204,661	16,829,153
22	Net assets or fund balances. Subtract line 21 from line 20.....	28,034,228	31,352,522

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 11,186,265 including grants of $ 5,211,638 ) (Revenue $ )
	Alzheimer's Disease Research (ADR) -- BrightFocus's ADR program funds research focused on understanding Alzheimer's disease's causes, its early detection, and treatments to help slow or stop its progression, and ultimately to prevent the disease altogether. ADR annually awards peer-reviewed grants to scientists from institutions worldwide who are conducting biomedical and clinical research on Alzheimer's disease.BrightFocus is honored to have supported the early research of two eventual Nobel Prize winners: Dr. Stanley Prusiner and Dr. Paul Greengard, whose work has been instrumental to our current understanding of Alzheimer's disease. Further illustrating BrightFocus's impact, a third-party roster of papers that considered milestones in Alzheimer's disease lists 19 BrightFocus-supported papers, six percent of the total recognized.During the fiscal year ended March 31, 2014, ADR grants included funding for 25 new projects, totaling $5,071,638, and awarded $136,000 for four special projects, including big data approaches to Alzheimer's disease and research into the basis of gender differences in risk of Alzheimer's. Additional information about specific projects are included in Schedules F & I.BrightFocus continues to develop its partnership with the academic journal "Molecular Neurodegeneration" as the official journal of the BrightFocus Foundation. The journal publishes technical papers primarily on topics related to the ADR program. As an "open access" journal, there is no fee for readers, and all content is freely available through its website. This ensures maximal exposure of journal contents to scientists and care providers world-wide.ADR-supported research made the news in this fiscal year, including high visibility reports relating diabetes drugs to severity of Alzheimer's disease, and pointing to reasons why current drugs fail to address the underlying causes of Alzheimer's. Both areas of research are the subject of ongoing BrightFocus funded clinical trials. More details are available in the news updates section of the BrightFocus.org website.In addition to supporting cutting-edge research, Alzheimer's Disease Research provides excellent resources on detecting, treating, and living with the disease. Alzheimer's disease ranks as at least the sixth leading cause of death in the United States, yet it is the only cause of death among the top 10 in America without a way to prevent, cure, or even slow its progression. It is an irreversible degeneration of the brain that causes disruptions in memory, cognition, personality, and other functions and inevitably leads to death. More than 5 million Americans aged 65 and older are thought to have Alzheimer's disease today, and that number is expected to triple in the next 40 years. Every 67 seconds, someone in America develops Alzheimer's. By mid-century, someone in America will develop the disease every 33 seconds.

4b	(Code: ) (Expenses $ 4,176,400 including grants of $ 1,945,400 ) (Revenue $ )
	Macular Degeneration Research (MDR), a program of BrightFocus, has awarded nearly $14 million to scientists studying the disease. The latest research is focused on novel treatments for the disease, understanding its causes and progression, drug therapies, and new screening techniques.During the fiscal year ending March 31, 2014, MDR grants included $1,920,000 in peer-reviewed grant awards to 16 new research projects that range from studies to simultaneously photograph and test the function of AMD affected retinas to those aimed at designing new cell-based therapies to target and eliminate the molecular changes that lead to macular degeneration. Additional details about specific projects are included in Schedule I.MDR-funded projects were featured in media articles, including progress in the development of a molecular switch to replace dying photoreceptors, as well as progress in treating the currently untreatable dry form of macular degeneration. More details on this and other successful outcomes achieved through MDR funding are available in the news updates section of the BrightFocus.org website.In addition to supporting cutting-edge research, Macular Degeneration Research provides excellent resources on detecting, treating, and living with this disease. Age-related macular degeneration is a leading cause of vision loss in the United States. It destroys the macula, the part of the eye that provides sharp, central vision needed for seeing objects clearly. The most common eye condition in people age 60 and older, it can lead to vision loss in one or both eyes, making it difficult to recognize faces, drive a car, or read.

4c	(Code: ) (Expenses $ 2,133,187 including grants of $ 1,598,277 ) (Revenue $ )
	BrightFocus's National Glaucoma Research (NGR) program has awarded more than $22.6 million worldwide for the study of glaucoma. NGR-supported research has been focused on the eye-brain connection, the mechanisms for pressure buildup in the eye, preventing damage to the optic nerve, and understanding the role genes play in order to develop early glaucoma screening and targeted treatments.NGR grants are available to glaucoma researchers worldwide. NGR places special emphasis on encouraging applications from young scientists and those with cutting-edge ideas. Annual grant applications are peer-reviewed, and recipient selections are based on scientific merit. During the fiscal year ending March 31, 2014, NGR awarded $1,398,277 for 14 new projects that range from calculating individual risk for glaucoma to real-time monitoring and control of pressure in the eye, a significant risk factor for glaucoma. In addition, the NGR program launched a $200,000 investigation into the suitability of two already existing drugs for potential ability to repair or enhance vision in glaucoma patients. Additional details about specific projects are included in Schedules F & I.NGR-funded research was recognized by the media this year, including an NGR supported strategy to block the accumulation of toxic proteins that can lead to early onset glaucoma. More details are available in the news updates section of the BrightFocus.org website.In addition to supporting cutting-edge research, National Glaucoma Research provides excellent resources on detecting, treating, and living with the disease. Glaucoma is a group of diseases that damage the eye's optic nerve and can result in vision loss and permanent blindness. More than 3 million Americans age 40 and older have glaucoma. More than 60 million people in the world have the disease, and that number is expected to increase by as much as 20 million by 2020. With early detection and treatment, glaucoma often can be managed to protect eyes from more serious vision loss, but it is estimated that only half of the people living with glaucoma are aware that they have the disease.

4d	Other program services (Describe in Schedule O.)
	(Expenses $ including grants of $ ) (Revenue $ )
4e	Total program service expenses17,495,852

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)............	962,593	0	231,776

				(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512-514
1a	Federated campaigns..1a		208,600
b	Membership dues....1b
c	Fundraising events....1c
d	Related organizations...1d
e	Government grants (contributions)1e

f	All other contributions, gifts, grants, and similar amounts not included above1f		24,917,633

g	Noncash contributions included in lines 1a-1f:$		28,644
h	Total. Add lines 1a-1f.......			25,126,233
			Business Code
2a
b
c
d
e
f	All other program service revenue .
g	Total. Add lines 2a–2f........
3	Investment income (including dividends, interest, and other similar amounts).......			665,408			665,408
4	Income from investment of tax-exempt bond proceeds..
5	Royalties...........			307,970			307,970
		(i) Real	(ii) Personal
6a	Gross rents	566,205
b	Less: rental expenses	43,705
c	Rental income or (loss)	522,500
d	Net rental income or (loss).......			522,500			522,500
		(i) Securities	(ii) Other
7a	Gross amount from sales of assets other than inventory	6,305,791
b	Less: cost or other basis and sales expenses	6,204,260
c	Gain or (loss)	101,531
d	Net gain or (loss)..........			101,531			101,531
8a	Gross income from fundraising events (not including $ of contributions reported on line 1c). See Part IV, line 18 ..
	a
b	Less: direct expenses ...b
c	Net income or (loss) from fundraising events..
9a	Gross income from gaming activities. See Part IV, line 19 ...
	a
b	Less: direct expenses ...b
c	Net income or (loss) from gaming activities...
10a	Gross sales of inventory, less returns and allowances .
	a
b	Less: cost of goods sold ..b
c	Net income or (loss) from sales of inventory..
Miscellaneous Revenue			Business Code
11a
b
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......
12	Total revenue. See Instructions......			26,723,642	0	0	1,597,409


				(A) Beginning of year		(B) End of year
1	Cash–non-interest-bearing .............			3,920,291	1	6,219,243
2	Savings and temporary cash investments .........			1,418,430	2	395,903
3	Pledges and grants receivable, net ...........			5,336,038	3	4,184,603
4	Accounts receivable, net .............				4
5	Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees. Complete Part II of Schedule L ..................
					5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete Part II of Schedule L
					6
7	Notes and loans receivable, net .............			176,008	7
8	Inventories for sale or use ..............			19,646	8	16,291
9	Prepaid expenses and deferred charges ..........			104,897	9	46,374
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	11,166,311
b	Less: accumulated depreciation .....	10b	2,781,227	8,602,822	10c	8,385,084
11	Investments—publicly traded securities ..........			19,464,859	11	24,677,383
12	Investments—other securities. See Part IV, line 11 .....			2,364,446	12	3,425,000
13	Investments—program-related. See Part IV, line 11 .....				13
14	Intangible assets ...............				14
15	Other assets. See Part IV, line 11 ...........			831,452	15	831,794
16	Total assets. Add lines 1 through 15 (must equal line 34)......			42,238,889	16	48,181,675
17	Accounts payable and accrued expenses .........			584,225	17	689,531
18	Grants payable .................			11,924,959	18	14,604,652
19	Deferred revenue ................				19
20	Tax-exempt bond liabilities .............				20
21	Escrow or custodial account liability. Complete Part IV of Schedule D..				21
22	Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified
	persons. Complete Part II of Schedule L..........				22
23	Secured mortgages and notes payable to unrelated third parties ..				23
24	Unsecured notes and loans payable to unrelated third parties ....				24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24). Complete Part X of Schedule D....................			1,695,477	25	1,534,970
26	Total liabilities. Add lines 17 through 25.........			14,204,661	26	16,829,153
	Organizations that follow SFAS 117 (ASC 958), check here and complete lines 27 through 29, and lines 33 and 34.
27	Unrestricted net assets ..............			15,916,258	27	18,308,429
28	Temporarily restricted net assets ...........			12,027,970	28	12,954,093
29	Permanently restricted net assets ...........			90,000	29	90,000
	Organizations that do not follow SFAS 117 (ASC 958), check here and complete lines 30 through 34.
30	Capital stock or trust principal, or current funds ........				30
31	Paid-in or capital surplus, or land, building or equipment fund .....				31
32	Retained earnings, endowment, accumulated income, or other funds				32
33	Total net assets or fund balances ...........			28,034,228	33	31,352,522
34	Total liabilities and net assets/fund balances ........			42,238,889	34	48,181,675

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes,"the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926)......................................	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A).......................................	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471)..............................	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621)...............................................	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships. (see Instructions for Form 8865)....................................	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to file Form 5713, International Boycott Report (see Instructions for Form 5713)................................................	Yes	No